U.S. patent number 9,617,246 [Application Number 15/105,808] was granted by the patent office on 2017-04-11 for thioether-piperidinyl orexin receptor antagonists.
This patent grant is currently assigned to MERCK SHARP & DOHME CORP.. The grantee listed for this patent is MERCK SHARP & DOHME CORP.. Invention is credited to Scott D. Kuduk, Jason W. Skudlarek.
United States Patent |
9,617,246 |
Kuduk , et al. |
April 11, 2017 |
Thioether-piperidinyl orexin receptor antagonists
Abstract
The present invention is directed to thioether-piperidinyl
compounds which are antagonists of orexin receptors. The present
invention is also directed to uses of the thioether-piperidinyl
compounds described herein in the potential treatment or prevention
of neurological and psychiatric disorders and diseases in which
orexin receptors are involved. The present invention is also
directed to pharmaceutical compositions comprising these compounds.
The present invention is also directed to uses of these
pharmaceutical compositions in the prevention or treatment of such
diseases in which orexin receptors are involved.
Inventors: |
Kuduk; Scott D. (Harleysville,
PA), Skudlarek; Jason W. (Audubon, PA) |
Applicant: |
Name |
City |
State |
Country |
Type |
MERCK SHARP & DOHME CORP. |
Rahway |
NJ |
US |
|
|
Assignee: |
MERCK SHARP & DOHME CORP.
(Rahway, NJ)
|
Family
ID: |
53403583 |
Appl.
No.: |
15/105,808 |
Filed: |
December 16, 2014 |
PCT
Filed: |
December 16, 2014 |
PCT No.: |
PCT/US2014/070463 |
371(c)(1),(2),(4) Date: |
June 17, 2016 |
PCT
Pub. No.: |
WO2015/095108 |
PCT
Pub. Date: |
June 25, 2015 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20160318899 A1 |
Nov 3, 2016 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
61917616 |
Dec 18, 2013 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D
401/14 (20130101); C07D 401/12 (20130101); C07D
409/14 (20130101); C07D 417/14 (20130101); C07D
405/14 (20130101) |
Current International
Class: |
C07D
401/14 (20060101); A61K 31/4545 (20060101); C07D
401/12 (20060101); C07D 405/14 (20060101); C07D
409/14 (20060101); C07D 417/14 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO2010048012 |
|
Apr 2010 |
|
WO |
|
JP2012-72067 |
|
Apr 2012 |
|
WO |
|
WO2013059163 |
|
Apr 2013 |
|
WO |
|
WO2014099696 |
|
Jun 2014 |
|
WO |
|
WO2014137883 |
|
Sep 2014 |
|
WO |
|
WO2014176142 |
|
Oct 2014 |
|
WO |
|
WO2014176144 |
|
Oct 2014 |
|
WO |
|
WO2014176146 |
|
Oct 2014 |
|
WO |
|
WO2015088864 |
|
Jun 2015 |
|
WO |
|
WO2015088865 |
|
Jun 2015 |
|
WO |
|
WO2015095108 |
|
Jun 2015 |
|
WO |
|
WO2015095442 |
|
Jun 2015 |
|
WO |
|
Other References
PubChem Compound, National Center for Biotechnology Information,
2010, Pubchem Database--CID=49759136. cited by applicant.
|
Primary Examiner: Barker; Michael
Attorney, Agent or Firm: Thies; J. Eric Todaro; John C.
Parent Case Text
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35
U.S.C. .sctn.371 of PCT Application No. PCT/U52014/070463, filed
Dec. 16, 2014, which claims priority under 35 U.S.C. .sctn.119(e)
from U.S. Ser. No. 61/917,616, filed Dec. 18, 2013.
Claims
What is claimed is:
1. A compound of the formula I: ##STR00057## wherein: A is selected
from the group consisting of phenyl, naphthyl and heteroaryl; X is
N or CH; R.sup.1a, R.sup.1b and R.sup.1c are independently selected
from the group consisting of: (1) hydrogen, (2) halogen, (3)
hydroxyl, (4) --(C.dbd.O).sub.m--O.sub.n--C.sub.1-6alkyl, where m
is 0 or 1, n is 0 or 1 (wherein if m is 0 or n is 0, a bond is
present) and where the alkyl is unsubstituted or substituted with
one or more substituents selected from R.sup.4, (5)
--(C.dbd.O).sub.m--O.sub.n--C.sub.3-6cycloalkyl, where the
cycloalkyl is unsubstituted or substituted with one or more
substituents selected from R.sup.4, (6)
--(C.dbd.O).sub.m--C.sub.2-4alkenyl, where the alkenyl is
unsubstituted or substituted with one or more substituents selected
from R.sup.4, (7) --(C.dbd.O).sub.m--C.sub.2-4alkynyl, where the
alkynyl is unsubstituted or substituted with one or more
substituents selected from R.sup.4, (8)
--(C.dbd.O).sub.m--O.sub.n-phenyl or
--(C.dbd.O).sub.m--O.sub.n-naphthyl, where the phenyl or naphthyl
is unsubstituted or substituted with one or more substituents
selected from R.sup.4, (9) --(C.dbd.O).sub.m--O.sub.n-heterocycle,
where the heterocycle is unsubstituted or substituted with one or
more substituents selected from R.sup.4, (10)
--(C.dbd.O).sub.m--NR.sup.10R.sup.11, wherein R.sup.10 and R.sup.11
are independently selected from the group consisting of: (a)
hydrogen, (b) C.sub.1-6alkyl, which is unsubstituted or substituted
with R.sup.4, (c) C.sub.3-6alkenyl, which is unsubstituted or
substituted with R.sup.4, (d) C.sub.3-6alkynyl, which is
unsubstituted or substituted with R.sup.4, (e) C.sub.3-6cycloalkyl
which is unsubstituted or substituted with R.sup.4, (f) phenyl,
which is unsubstituted or substituted with R.sup.4, and (g)
heterocycle, which is unsubstituted or substituted with R.sup.4,
(11) --S(O).sub.2--NR.sup.10R.sup.11, (12) --S(O).sub.q--R.sup.12,
where q is 0, 1 or 2 and where R.sup.12 is selected from the
definitions of R.sup.10 and R.sup.11, (13) --CO.sub.2H, (14) --CN,
and (15) --NO.sub.2; R.sup.3 is selected from C.sub.1-6alkyl and
C.sub.3-6cycloalkyl, which is unsubstituted or substituted with one
or more substituents selected from R.sup.4; R.sup.4 is selected
from the group consisting of: (1) hydroxyl, (2) halogen, (3)
C.sub.1-6alkyl, (4) --C.sub.3-6cycloalkyl, (5) --O--C.sub.1-6alkyl,
(6) --O(C.dbd.O)--C.sub.1-6alkyl, (7) --NH.sub.2, (8)
--NH--C.sub.1-6alkyl, (9) --NO.sub.2, (10) phenyl, (11)
--CO.sub.2H, and (12) --CN; R.sup.5 is selected from the group
consisting of: (1) hydrogen, (2) halogen, (3) --CN, (4)
--(C.dbd.O)--O--C.sub.1-6alkyl, which is unsubstituted or
substituted with halogen or phenyl, and (5) C.sub.1-6alkyl, which
is unsubstituted or substituted with halogen or phenyl; R.sup.6 is
selected from the group consisting of: (1) hydrogen, (2) halogen,
(3) --CN, (4) --(C.dbd.O)--O--C.sub.1-6alkyl, which is
unsubstituted or substituted with halogen or phenyl, and (5)
C.sub.1-6alkyl, which is unsubstituted or substituted with halogen
or phenyl; R.sup.7 is selected from the group consisting of: (1)
hydrogen, and (2) C.sub.1-6alkyl; or a pharmaceutically acceptable
salt thereof.
2. The compound of claim 1 of the formula Ia: ##STR00058## or a
pharmaceutically acceptable salt thereof.
3. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.1a, R.sup.1b and R.sup.1c are independently
selected from the group consisting of: (1) hydrogen, (2) halogen,
(3) hydroxyl, (4) C.sub.1-6alkyl, which is unsubstituted or
substituted with halogen, hydroxyl or phenyl, (5)
--O--C.sub.1-6alkyl, which is unsubstituted or substituted with
halogen, hydroxyl or phenyl, (6) --CN, and (7) heteroaryl, wherein
heteroaryl is selected from imidazolyl, indolyl, oxazolyl, pyridyl,
pyrrolyl, pyrimidinyl, tetrazolyl, and triazolyl, which is
unsubstituted or substituted with halogen, hydroxyl,
C.sub.1-6alkyl, --O--C.sub.1-6alkyl or --NO.sub.2.
4. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.3 is methyl.
5. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.5 is selected from the group consisting of:
(1) hydrogen, (2) halogen, (3) --CN, (4)
--(C.dbd.O)--O--C.sub.1-6alkyl, and (5) C.sub.1-6alkyl, which is
unsubstituted or substituted with halogen.
6. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.6 is selected from the group consisting of:
(1) hydrogen, (2) --CN, and (3) --(C.dbd.O)--O--C.sub.1-6alkyl.
7. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.5 is --CN and R.sup.6 is hydrogen.
8. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.5 is --O--CH.sub.3 and R.sup.6 is
--(C.dbd.O)--O--CH.sub.3.
9. The compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.7 is hydrogen.
10. A compound which is selected from the group consisting of:
methyl
4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}-piperidin-3-yl]sulfanyl}pyridine-3-carboxylate;
2-methyl-6-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile; methyl
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine-3-carboxylate; methyl
4-iodo-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-
piperidin-3-yl]sulfanyl}pyridine-3-carboxylate;
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine;
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}-5-(trifluoromethyl)pyridine;
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine-4-carbonitrile;
4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine-3-carbonitrile;
4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine;
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine-3-carbonitrile; methyl
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine-4-carboxylate;
2-{[(3R,6R)-1-{[6-methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl]carbonyl}-
-6-methylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[4-(2H-1,2,3-triazol-2-yl)pyridin-3-yl]carbonyl}p-
iperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-meth-
ylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-met-
hylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-meth-
ylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-meth-
ylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-meth-
ylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-met-
hylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[5-bromo-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-methy-
lpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-meth-
ylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
3-({(2R,5R)-5-[(4-cyanopyridin-2-yl)sulfanyl]-2-methylpiperidin-1-yl}carb-
onyl)-4-(2H-1,2,3-triazol-2-yl)benzamide;
2-{[(3R,6R)-6-methyl-1-{[4-(2H-1,2,3-triazol-2-yl)isothiazol-3-yl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-(biphenyl-2-ylcarbonyl)-6-methylpiperidin-3-yl]sulfanyl}pyr-
idine-4-carbonitrile;
2-({(3R,6R)-6-methyl-1-[(2-phenoxyphenyl)carbonyl]piperidin-3-yl}sulfanyl-
)pyridine-4-carbonitrile;
2-({(3R,6R)-1-[(2-cyclopropylphenyl)carbonyl]-6-methylpiperidin-3-yl}sulf-
anyl)pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(1-methyl-1H-pyrazol-4-yl)phenyl]carbonyl}pipe-
ridin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-({(3R,6R)-6-methyl-1-[(2-phenylpyridin-3-yl)carbonyl]piperidin-3-yl}sul-
fanyl)pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(1-methylethoxy)phenyl]carbonyl}piperidin-3-yl-
]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(methyl
sulfanyl)phenyl]carbonyl}piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[4-cyano-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-methy-
lpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-1-{[4-ethoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-6-meth-
ylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(tetrahydro-2H-pyran-4-yl)phenyl]carbonyl}pipe-
ridin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(tetrahydro-2H-pyran-2-yl)phenyl]carbonyl}pipe-
ridin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-({(3R,6R)-6-methyl-1-[(2-pyrrolidin-1-ylphenyl)carbonyl]piperidin-3-yl}-
sulfanyl)pyridine-4-carbonitrile;
2-({(3R,6R)-6-methyl-1-[(2-pyrimidin-2-ylthiophen-3-yl)carbonyl]piperidin-
-3-yl}sulfanyl)pyridine-4-carbonitrile;
2-({(3R,6R)-6-methyl-1-[(2-pyrimidin-2-ylphenyl)carbonyl]piperidin-3-yl}s-
ulfanyl)pyridine-4-carbonitrile;
2-({(3R,6R)-6-methyl-1-[(3-pyrimidin-2-ylthiophen-2-yl)carbonyl]piperidin-
-3-yl}sulfanyl)pyridine-4-carbonitrile;
2-({(3R,6R)-1-[(6-methoxy-2-pyrimidin-2-ylpyridin-3-yl)carbonyl]-6-methyl-
piperidin-3-yl}sulfanyl)pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)thiophen-3-yl]carbonyl}-
piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile;
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine-3-carboxylic acid; and methyl
4-methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbon-
yl}-piperidin-3-yl]sulfanyl}pyridine-3-carboxylate; or a
pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition which comprises an inert carrier
and a compound of claim 1 or a pharmaceutically acceptable salt
thereof.
12. A method for enhancing the quality of sleep in a mammalian
patient in need thereof which comprises administering to the
patient a therapeutically effective amount of the compound of claim
1 or a pharmaceutically acceptable salt thereof.
13. A method for treating insomnia in a mammalian patient in need
thereof which comprises administering to the patient a
therapeutically effective amount of the compound of claim 1 or a
pharmaceutically acceptable salt thereof.
14. A method for treating or controlling obesity in a mammalian
patient in need thereof which comprises administering to the
patient a therapeutically effective amount of the compound of claim
1 or a pharmaceutically acceptable salt thereof.
Description
BACKGROUND OF THE INVENTION
The orexins (hypocretins) comprise two neuropeptides produced in
the hypothalamus: the orexin A (OX-A) (a 33 amino acid peptide) and
the orexin B (OX-B) (a 28 amino acid peptide) (Sakurai T. et al.,
Cell, 1998, 92, 573-585). Orexins are found to stimulate food
consumption in rats suggesting a physiological role for these
peptides as mediators in the central feedback mechanism that
regulates feeding behavior (Sakurai T. et al., Cell, 1998, 92,
573-585). Orexins regulate states of sleep and wakefulness opening
potentially novel therapeutic approaches for narcoleptic or
insomniac patients (Chemelli R. M. et al., Cell, 1999, 98,
437-451). Orexins have also been indicated as playing a role in
arousal, reward, learning and memory (Harris, et al., Trends
Neurosci., 2006, 29 (10), 571-577). Two orexin receptors have been
cloned and characterized in mammals. They belong to the super
family of G-protein coupled receptors (Sakurai T. et al., Cell,
1998, 92, 573-585): the orexin-1 receptor (OX or OX1R) is selective
for OX-A and the orexin-2 receptor (OX2 or OX2R) is capable to bind
OX-A as well as OX-B. The physiological actions in which orexins
are presumed to participate are thought to be expressed via one or
both of OX1 receptor and OX2 receptor as the two subtypes of orexin
receptors.
SUMMARY OF THE INVENTION
The present invention is directed to thioether-piperidinyl
compounds which are antagonists of orexin receptors. The present
invention is also directed to uses of the thioether-piperidinyl
compounds described herein in the potential treatment or prevention
of neurological and psychiatric disorders and diseases in which
orexin receptors are involved. The present invention is also
directed to pharmaceutical compositions comprising these compounds.
The present invention is also directed to uses of these
pharmaceutical compositions in the prevention or treatment of such
diseases in which orexin receptors are involved.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compounds of the formula
I:
##STR00001## wherein: A is selected from the group consisting of
phenyl, naphthyl and heteroaryl; X is N or CH; R.sup.1a, R.sup.1b
and R.sup.1c are independently selected from the group consisting
of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4)
--(C.dbd.O).sub.m--O.sub.n--C.sub.1-6alkyl, where m is 0 or 1, n is
0 or 1 (wherein if m is 0 or n is 0, a bond is present) and where
the alkyl is unsubstituted or substituted with one or more
substituents selected from R.sup.4, (5)
--(C.dbd.O).sub.m--O.sub.n--C.sub.3-6cycloalkyl, where the
cycloalkyl is unsubstituted or substituted with one or more
substituents selected from R.sup.4, (6)
--(C.dbd.O).sub.m--C.sub.2-4 alkenyl, where the alkenyl is
unsubstituted or substituted with one or more substituents selected
from R.sup.4, (7) --(C.dbd.O).sub.m--C.sub.2-4 alkynyl, where the
alkynyl is unsubstituted or substituted with one or more
substituents selected from R.sup.4, (8)
--(C.dbd.O).sub.m--O.sub.n-phenyl or
--(C.dbd.O).sub.m--O.sub.n-naphthyl, where the phenyl or naphthyl
is unsubstituted or substituted with one or more substituents
selected from R.sup.4, (9) --(C.dbd.O).sub.m--O.sub.n-heterocycle,
where the heterocycle is unsubstituted or substituted with one or
more substituents selected from R.sup.4, (10)
--(C.dbd.O).sub.m--NR.sup.10R.sup.11, wherein R.sup.10 and R.sup.11
are independently selected from the group consisting of: (a)
hydrogen, (b) C.sub.1-6alkyl, which is unsubstituted or substituted
with R.sup.4, (c) C.sub.3-6alkenyl, which is unsubstituted or
substituted with R.sup.4, (d) C.sub.3-6 alkynyl, which is
unsubstituted or substituted with R.sup.4, (e) C.sub.3-6cycloalkyl
which is unsubstituted or substituted with R.sup.4, (f) phenyl,
which is unsubstituted or substituted with R.sup.4, and (g)
heterocycle, which is unsubstituted or substituted with R.sup.4,
(11) --S(O).sub.2--NR.sup.10R.sup.11, (12) --S(O).sub.q--R.sup.12,
where q is 0, 1 or 2 and where R.sup.12 is selected from the
definitions of R.sup.10 and R.sup.11, (13) --CO.sub.2H, (14) --CN,
and (15) --NO.sub.2; R.sup.3 is selected from C.sub.1-6alkyl and
C.sub.3-6cycloalkyl, which is unsubstituted or substituted with one
or more substituents selected from R.sup.4; R.sup.4 is selected
from the group consisting of: (1) hydroxyl, (2) halogen, (3)
C.sub.1-6alkyl, (4) --C.sub.3-6cycloalkyl, (5) --O--C.sub.1-6alkyl,
(6) --O(C.dbd.O)--C.sub.1-6alkyl, (7) --NH.sub.2, (8)
--NH--C.sub.1-6alkyl, (9) --NO.sub.2, (10) phenyl, (11)
--CO.sub.2H, and (12) --CN; R.sup.5 is selected from the group
consisting of: (1) hydrogen, (2) halogen, (3) --CN, (4)
--(C.dbd.O)--O--C.sub.1-6alkyl, which is unsubstituted or
substituted with halogen or phenyl, and (5) C.sub.1-6alkyl, which
is unsubstituted or substituted with halogen or phenyl; R.sup.6 is
selected from the group consisting of: (1) hydrogen, (2) halogen,
(3) --CN, (4) --(C.dbd.O)--O--C.sub.1-6alkyl, which is
unsubstituted or substituted with halogen or phenyl, and (5)
C.sub.1-6alkyl, which is unsubstituted or substituted with halogen
or phenyl; R.sup.7 is selected from the group consisting of: (1)
hydrogen, and (2) C.sub.1-6alkyl; or a pharmaceutically acceptable
salt thereof.
An embodiment of the present invention includes compounds of the
formula Ia:
##STR00002## wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.3,
R.sup.5, R.sup.6 and X are defined herein; or a pharmaceutically
acceptable salt thereof.
An embodiment of the present invention includes compounds of the
formula Ia':
##STR00003## wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.3,
R.sup.5, R.sup.6 and X are defined herein; or a pharmaceutically
acceptable salt thereof.
An embodiment of the present invention includes compounds of the
formula Ia'':
##STR00004## wherein R.sup.1a, R.sup.1b, R.sup.1c, R.sup.3,
R.sup.5, R.sup.6 and X are defined herein; or a pharmaceutically
acceptable salt thereof.
An embodiment of the present invention includes compounds of the
formula Ib:
##STR00005## wherein R.sup.1a, R.sup.1b, R.sup.3, R.sup.5 and
R.sup.6 are defined herein; or a pharmaceutically acceptable salt
thereof.
An embodiment of the present invention includes compounds of the
formula Ib':
##STR00006## wherein R.sup.1a, R.sup.1b, R.sup.3, R.sup.5 and
R.sup.6 are defined herein; or a pharmaceutically acceptable salt
thereof.
An embodiment of the present invention includes compounds of the
formula Ib'':
##STR00007## wherein R.sup.1a, R.sup.1b, R.sup.3, R.sup.5 and
R.sup.6 are defined herein; or a pharmaceutically acceptable salt
thereof.
An embodiment of the present invention includes compounds wherein A
is selected from phenyl, pyridyl, thiophenyl, thiazolyl,
isothiazolyl, and pyrazolyl. An embodiment of the present invention
includes compounds wherein A is phenyl. An embodiment of the
present invention includes compounds wherein A is pyridyl. An
embodiment of the present invention includes compounds wherein A is
thiophenyl. An embodiment of the present invention includes
compounds wherein A is thiazolyl. An embodiment of the present
invention includes compounds wherein A is isothiazolyl. An
embodiment of the present invention includes compounds wherein A is
pyrazolyl.
An embodiment of the present invention includes compounds wherein
R.sup.1a, R.sup.1b and R.sup.1c are independently selected from the
group consisting of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4)
C.sub.1-6alkyl, which is unsubstituted or substituted with halogen,
hydroxyl or phenyl, (5) --O--C.sub.1-6alkyl, which is unsubstituted
or substituted with halogen, hydroxyl or phenyl, (6) heteroaryl,
wherein heteroaryl is selected from imidazolyl, indolyl, oxazolyl,
pyridyl, pyrrolyl, pyrimidinyl, tetrazolyl, and triazolyl, which is
unsubstituted or substituted with halogen, hydroxyl,
C.sub.1-6alkyl, --O--C.sub.1-6alkyl or --NO.sub.2, (7) phenyl,
which is unsubstituted or substituted with halogen, hydroxyl,
C.sub.1-6alkyl, --O--C.sub.1-6alkyl or --NO.sub.2, (8) --O-phenyl,
which is unsubstituted or substituted with halogen, hydroxyl,
C.sub.1-6alkyl, --O--C.sub.1-6alkyl or --NO.sub.2, (9) --CN, and
(10) --NH--C.sub.1-6alkyl, or --N(C.sub.1-6alkyl)(C.sub.1-6alkyl),
which is unsubstituted or substituted with halogen, hydroxyl,
C.sub.1-6alkyl, and --O--C.sub.1-6alkyl.
An embodiment of the present invention includes compounds wherein
R.sup.1a, R.sup.1b and R.sup.1c are independently selected from the
group consisting of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4)
C.sub.1-6alkyl, which is unsubstituted or substituted with halogen,
hydroxyl or phenyl, (5) --O--C.sub.1-6alkyl, which is unsubstituted
or substituted with halogen, hydroxyl or phenyl, (6) --CN, and (7)
heteroaryl, wherein heteroaryl is selected from imidazolyl,
indolyl, oxazolyl, pyridyl, pyrrolyl, pyrimidinyl, tetrazolyl, and
triazolyl, which is unsubstituted or substituted with halogen,
hydroxyl, C.sub.1-6alkyl, --O--C.sub.1-6 alkyl or --NO.sub.2.
An embodiment of the present invention includes compounds wherein
R.sup.1a, R.sup.1b and R.sup.1c are independently selected from the
group consisting of: (1) hydrogen, (2) halogen, (3) C.sub.1-6alkyl,
which is unsubstituted or substituted with halogen, (4)
--O--C.sub.1-6alkyl, which is unsubstituted or substituted with
halogen, (5) --CN, and (6) heteroaryl, wherein heteroaryl is
selected from imidazolyl, indolyl, oxazolyl, pyridyl, pyrrolyl,
pyrimidinyl, tetrazolyl, and triazolyl.
An embodiment of the present invention includes compounds wherein
R.sup.1c is hydrogen, and R.sup.1a and R.sup.1b are independently
selected from the group consisting of: (1) hydrogen, (2) fluoro,
(3) chloro, (4) bromo, (5) methyl, (6) ethyl, (7) methoxy, (8)
trifluoromethyl, and (9) heteroaryl, wherein heteroaryl is selected
from imidazolyl, indolyl, oxazolyl, pyridyl, pyrrolyl, pyrimidinyl,
tetrazolyl, and triazolyl,
An embodiment of the present invention includes compounds wherein
R.sup.1c is hydrogen, and R.sup.1a and R.sup.1b are independently
selected from the group consisting of: (1) hydrogen, (2) fluoro,
(3) chloro, (4) methyl, (5) methoxy, (6) tetrazolyl, and (7)
triazolyl.
An embodiment of the present invention includes compounds wherein
R.sup.3 is C.sub.1-6alkyl. An embodiment of the present invention
includes compounds wherein R.sup.3 is C.sub.3-6cycloalkyl. An
embodiment of the present invention includes compounds wherein
R.sup.3 is methyl or ethyl. An embodiment of the present invention
includes compounds wherein R.sup.3 is methyl. An embodiment of the
present invention includes compounds wherein R.sup.3 is
(R)-methyl.
An embodiment of the present invention includes compounds wherein
R.sup.5 is selected from the group consisting of: (1) hydrogen, (2)
halogen, (3) --CN, (4) --(C.dbd.O)--O--C.sub.1-6alkyl, and (5)
C.sub.1-6alkyl, which is unsubstituted or substituted with
halogen.
An embodiment of the present invention includes compounds wherein
R.sup.5 is selected from the group consisting of: hydrogen, --CN,
methyl, trifluoro-methyl, --(C.dbd.O)--O--CH.sub.3, and
--O--CH.sub.3.
An embodiment of the present invention includes compounds wherein
R.sup.5 is --CN. An embodiment of the present invention includes
compounds wherein R.sup.5 is methyl. An embodiment of the present
invention includes compounds wherein R.sup.5 is --O--CH.sub.3.
An embodiment of the present invention includes compounds wherein
R.sup.6 is selected from the group consisting of: (1) hydrogen, (2)
--CN, and (3) --(C.dbd.O)--O--C.sub.1-6alkyl.
An embodiment of the present invention includes compounds wherein
R.sup.6 is selected from the group consisting of: hydrogen, --CN,
and --(C.dbd.O)--O--CH.sub.3.
An embodiment of the present invention includes compounds wherein
R.sup.6 is --CN. An embodiment of the present invention includes
compounds wherein R.sup.6 is hydrogen. An embodiment of the present
invention includes compounds wherein R.sup.6 is
--(C.dbd.O)--O--CH.sub.3.
An embodiment of the present invention includes compounds wherein
R.sup.5 is --CN and R.sup.6 is hydrogen.
An embodiment of the present invention includes compounds wherein
R.sup.5 is --O--CH.sub.3 and R.sup.6 is
--(C.dbd.O)--O--CH.sub.3.
An embodiment of the present invention includes compounds wherein
R.sup.7 is hydrogen or methyl. An embodiment of the present
invention includes compounds wherein R.sup.7 is hydrogen.
Certain embodiments of the present invention include a compound
which is selected from the group consisting of the subject
compounds of the Examples herein or a pharmaceutically acceptable
salt thereof.
The compounds of the present invention may contain one or more
asymmetric centers and can thus occur as racemates and racemic
mixtures, single enantiomers, diastereomeric mixtures and
individual diastereomers. Additional asymmetric centers may be
present depending upon the nature of the various substituents on
the molecule. Each such asymmetric center will independently
produce two optical isomers and it is intended that all of the
possible optical isomers and diastereomers in mixtures and as pure
or partially purified compounds are included within the ambit of
this invention. The present invention is meant to comprehend all
such isomeric forms of these compounds. Formula I shows the
structure of the class of compounds without specific
stereochemistry.
The independent syntheses of these diastereomers or their
chromatographic separations may be achieved as known in the art by
appropriate modification of the methodology disclosed herein. Their
absolute stereochemistry may be determined by the x-ray
crystallography of crystalline products or crystalline
intermediates which are derivatized, if necessary, with a reagent
containing an asymmetric center of known absolute configuration. If
desired, racemic mixtures of the compounds may be separated so that
the individual enantiomers are isolated. The separation can be
carried out by methods well known in the art, such as the coupling
of a racemic mixture of compounds to an enantiomerically pure
compound to form a diastereomeric mixture, followed by separation
of the individual diastereomers by standard methods, such as
fractional crystallization or chromatography. The coupling reaction
is often the formation of salts using an enantiomerically pure acid
or base. The diasteromeric derivatives may then be converted to the
pure enantiomers by cleavage of the added chiral residue. The
racemic mixture of the compounds can also be separated directly by
chromatographic methods utilizing chiral stationary phases, which
methods are well known in the art. Alternatively, any enantiomer of
a compound may be obtained by stereoselective synthesis using
optically pure starting materials or reagents of known
configuration by methods well known in the art.
As appreciated by those of skill in the art, halogen or halo as
used herein are intended to include fluoro, chloro, bromo and iodo.
Similarly, C.sub.1-6, as in C.sub.1-6alkyl is defined to identify
the group as having 1, 2, 3, 4, 5 or 6 carbons in a linear or
branched arrangement, such that C.sub.1-6alkyl specifically
includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl,
tert-butyl, pentyl, and hexyl. A group which is designated as being
independently substituted with substituents may be independently
substituted with multiple numbers of such substituents. The term
"heterocycle" as used herein includes both unsaturated (i.e.
"heteroaryl") and saturated heterocyclic moieties, wherein the
unsaturated heterocyclic moieties include benzoimidazolyl,
benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl,
benzothiazolyl, benzotriazolyl, benzothiophenyl, benzoxazepin,
benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl,
imidazolyl, indolinyl, indolyl, dihydroindolyl, indolazinyl,
indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl,
isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline,
isoxazoline, oxetanyl, pyrazinyl, pyrazolyl, pyridazinyl,
pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl,
quinazolinyl, quinolyl, quinoxalinyl, tetrahydroquinoxalinyl,
tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl,
triazolyl, and N-oxides thereof, and wherein the saturated
heterocyclic moieties include azetidinyl, 1,4-dioxanyl,
hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl,
pyrrolidinyl, morpholinyl, tetrahydrofuranyl, thiomorpholinyl, and
tetrahydrothienyl, and N-oxides thereof.
The present invention also includes all pharmaceutically acceptable
isotopic variations of a compound of the Formula I in which one or
more atoms is replaced by atoms having the same atomic number, but
an atomic mass or mass number different from the atomic mass or
mass number usually found in nature. Examples of isotopes suitable
for inclusion in the compounds of the invention include isotopes of
hydrogen such as .sup.2H and .sup.3H, carbon such as .sup.11C,
.sup.13C and .sup.14C, nitrogen such as .sup.13N and .sup.15N,
oxygen such as .sup.15O, .sup.17O and .sup.18O, phosphorus such as
.sup.32P, sulfur such as .sup.35S, fluorine such as .sup.18F,
iodine such as .sup.123I and .sup.125I, and chlorine such as
.sup.36Cl. Certain isotopically-labelled compounds of Formula I,
for example those incorporating a radioactive isotope, are useful
in drug and/or substrate tissue distribution studies. The
radioactive isotopes tritium, i.e. .sup.3H, and carbon-14, i.e.
.sup.14C, are particularly useful for this purpose in view of their
ease of incorporation and ready means of detection. Substitution
with heavier isotopes such as deuterium, i.e. .sup.2H, may afford
certain therapeutic advantages resulting from greater metabolic
stability, for example, increased in vivo half-life or reduced
dosage requirements, and hence may be preferred in some
circumstances. Substitution with positron emitting isotopes, such
as .sup.11C, .sup.18F, .sup.15O and .sup.13N, can be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy. Isotopically-labelled compounds of Formula I
can generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the accompanying Examples using appropriate isotopically-labelled
reagents in place of the non-labelled reagent previously
employed.
The term "pharmaceutically acceptable salts" refers to salts
prepared from pharmaceutically acceptable non-toxic bases or acids
including inorganic or organic bases and inorganic or organic
acids. Salts derived from inorganic bases include aluminum,
ammonium, calcium, copper, ferric, ferrous, lithium, magnesium,
manganic salts, manganous, potassium, sodium, zinc, and the like.
Particular embodiments include the ammonium, calcium, magnesium,
potassium, and sodium salts. Salts in the solid form may exist in
more than one crystal structure, and may also be in the form of
hydrates. Salts derived from pharmaceutically acceptable organic
non-toxic bases include salts of primary, secondary, and tertiary
amines, substituted amines including naturally occurring
substituted amines, cyclic amines, and basic ion exchange resins,
such as arginine, betaine, caffeine, choline,
N,N'-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol,
2-dimethylaminoethanol, ethanolamine, ethylenediamine,
N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine,
histidine, hydrabamine, isopropylamine, lysine, methylglucamine,
morpholine, piperazine, piperidine, polyamine resins, procaine,
purines, theobromine, triethylamine, trimethylamine,
tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be
prepared from pharmaceutically acceptable non-toxic acids,
including inorganic and organic acids. Such acids include acetic,
benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic,
fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic,
lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric,
pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric,
p-toluenesulfonic acid, and the like. Particular embodiments
include the citric, hydrobromic, hydrochloric, maleic, phosphoric,
sulfuric, fumaric, and tartaric acids. It will be understood that,
as used herein, references to the compounds of Formula I are meant
to also include the pharmaceutically acceptable salts.
Exemplifying the invention is the use of the compounds disclosed in
the Examples and herein. Specific compounds within the present
invention include a compound which selected from the group
consisting of the compounds disclosed in the following Examples and
pharmaceutically acceptable salts thereof and individual
enantiomers or diastereomers thereof.
The subject compounds are useful in a method of antagonizing orexin
receptor activity in a patient such as a mammal in need of such
inhibition comprising the administration of an effective amount of
the compound. The present invention is directed to the use of the
compounds disclosed herein as antagonists of orexin receptor
activity. In addition to primates, especially humans, a variety of
other mammals may be treated according to the method of the present
invention. The present invention is directed to a compound of the
present invention or a pharmaceutically acceptable salt thereof
that could be useful in medicine. The present invention may further
be directed to a use of a compound of the present invention or a
pharmaceutically acceptable salt thereof for the manufacture of a
medicament for antagonizing orexin receptor activity or treating
the disorders and diseases noted herein in humans and animals.
The subject treated in the present methods is generally a mammal,
such as a human being, male or female. The term "therapeutically
effective amount" means the amount of the subject compound that
will elicit the biological or medical response of a tissue, system,
animal or human that is being sought by the researcher,
veterinarian, medical doctor or other clinician. It is recognized
that one skilled in the art may affect the neurological and
psychiatric disorders by treating a patient presently afflicted
with the disorders or by prophylactically treating a patient
afflicted with the disorders with an effective amount of the
compound of the present invention. As used herein, the terms
"treatment" and "treating" refer to all processes wherein there may
be a slowing, interrupting, arresting, controlling, or stopping of
the progression of the neurological and psychiatric disorders
described herein, but does not necessarily indicate a total
elimination of all disorder symptoms, as well as the prophylactic
therapy of the mentioned conditions, particularly in a patient who
is predisposed to such disease or disorder. The terms
"administration of" and or "administering a" compound should be
understood to mean providing a compound of the invention or a
prodrug of a compound of the invention to the individual in need
thereof.
The term "composition" as used herein is intended to encompass a
product comprising the specified ingredients in the specified
amounts, as well as any product which results, directly or
indirectly, from combination of the specified ingredients in the
specified amounts. Such term in relation to pharmaceutical
composition, is intended to encompass a product comprising the
active ingredient(s), and the inert ingredient(s) that make up the
carrier, as well as any product which results, directly or
indirectly, from combination, complexation or aggregation of any
two or more of the ingredients, or from dissociation of one or more
of the ingredients, or from other types of reactions or
interactions of one or more of the ingredients. Accordingly, the
pharmaceutical compositions of the present invention encompass any
composition made by admixing a compound of the present invention
and a pharmaceutically acceptable carrier. By "pharmaceutically
acceptable" it is meant the carrier, diluent or excipient must be
compatible with the other ingredients of the formulation and not
deleterious to the recipient thereof.
The utility of the compounds in accordance with the present
invention as orexin receptor OX1R and/or OX2R antagonists may be
readily determined without undue experimentation by methodology
well known in the art, including the "FLIPR Ca.sup.2+ Flux Assay"
(Okumura et al., Biochem. Biophys. Res. Comm. 280:976-981, 2001).
In a typical experiment the OX1 and OX2 receptor antagonistic
activity of the compounds of the present invention was determined
in accordance with the following experimental method. For
intracellular calcium measurements, Chinese hamster ovary (CHO)
cells expressing the rat orexin-1 receptor or the human orexin-2
receptor, are grown in Iscove's modified DMEM containing 2 mM
L-glutamine, 0.5 g/ml G418, 1% hypoxanthine-thymidine supplement,
100 U/ml penicillin, 100 .mu.g/ml streptomycin and 10%
heat-inactivated fetal calf serum (FCS). The cells are seeded at
20,000 cells/well into Becton-Dickinson black 384-well clear bottom
sterile plates coated with poly-D-lysine. All reagents were from
GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at
37.degree. C. and 5% CO2. Ala-6,12 human orexin-A as the agonist is
prepared as a 1 mM stock solution in 1% bovine serum albumin (BSA)
and diluted in assay buffer (HBSS containing 20 mM HEPES, 0.1% BSA
and 2.5 mM probenecid, pH7.4) for use in the assay at a final
concentration of 70 pM. Test compounds are prepared as 10 mM stock
solution in DMSO, then diluted in 384-well plates, first in DMSO,
then assay buffer. On the day of the assay, cells are washed 3
times with 100 .mu.l assay buffer and then incubated for 60 min
(37.degree. C., 5% CO2) in 60 .mu.l assay buffer containing 1 .mu.M
Fluo-4AM ester, 0.02% pluronic acid, and 1% BSA. The dye loading
solution is then aspirated and cells are washed 3 times with 100
.mu.l assay buffer. 30 .mu.l of that same buffer is left in each
well. Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular
Devices), test compounds are added to the plate in a volume of 25
.mu.l, incubated for 5 min and finally 25 .mu.l of agonist is
added. Fluorescence is measured for each well at 1 second intervals
for 5 minutes and the height of each fluorescence peak is compared
to the height of the fluorescence peak induced by 70 pM Ala-6,12
orexin-A with buffer in place of antagonist. For each antagonist,
IC50 value (the concentration of compound needed to inhibit 50% of
the agonist response) is determined. Alternatively, compound
potency can be assessed by a radioligand binding assay (described
in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in
which the inhibition constant (K.sub.i) is determined in membranes
prepared from CHO cells expressing either the OX1 or OX2 receptor.
The intrinsic orexin receptor antagonist activity of a compound
which may be used in the present invention may be determined by
these assays.
All of the final compounds of the following examples had activity
in antagonizing the human orexin-2 receptor in the aforementioned
assays with an IC.sub.50 of about 0.1 nM to 100 nM. All of the
final compounds of the following examples had activity in the
radioligand binding assay with a Ki of about 0.1 nM to 100 nM
against the orexin-2 receptor. All of the final compounds of the
following examples had activity in the FLIPR assay with an IC50 of
about 0.1 nM to 100 nM against the orexin-2 receptor. Additional
data is provided in the following Examples. Such a result is
indicative of the intrinsic activity of the compounds in use as
antagonists of orexin-1 receptor and/or the orexin-2 receptor. In
general, one of ordinary skill in the art would appreciate that a
substance is considered to effectively antagonize the orexin
receptor if it has an IC50 of less than about 50 .mu.M, preferably
less than about 100 nM. With respect to other piperidine compounds,
it would be desirable that the present compounds exhibit unexpected
properties, such as increased selectivity at the orexin-2 receptor
relative to the orexin-1 receptor.
The orexin receptors have been implicated in a wide range of
biological functions. This has suggested a potential role for these
receptors in a variety of disease processes in humans or other
species. The compounds of the present invention could therefore
potentially have utility in treating, preventing, ameliorating,
controlling or reducing the risk of a variety of neurological and
psychiatric disorders associated with orexin receptors, including
one or more of the following conditions or diseases: sleep
disorders, sleep disturbances, including enhancing sleep quality,
improving sleep quality, increasing sleep efficiency, augmenting
sleep maintenance; increasing the value which is calculated from
the time that a subject sleeps divided by the time that a subject
is attempting to sleep; improving sleep initiation; decreasing
sleep latency or onset (the time it takes to fall asleep);
decreasing difficulties in falling asleep; increasing sleep
continuity; decreasing the number of awakenings during sleep;
decreasing intermittent wakings during sleep; decreasing nocturnal
arousals; decreasing the time spent awake following the initial
onset of sleep; increasing the total amount of sleep; reducing the
fragmentation of sleep; altering the timing, frequency or duration
of REM sleep bouts; altering the timing, frequency or duration of
slow wave (i.e. stages 3 or 4) sleep bouts; increasing the amount
and percentage of stage 2 sleep; promoting slow wave sleep;
enhancing EEG-delta activity during sleep; decreasing nocturnal
arousals, especially early morning awakenings; increasing daytime
alertness; reducing daytime drowsiness; treating or reducing
excessive daytime sleepiness; increasing satisfaction with the
intensity of sleep; increasing sleep maintenance; idiopathic
insomnia; sleep problems; insomnia, hypersomnia, idiopathic
hypersomnia, repeatability hypersomnia, intrinsic hypersomnia,
narcolepsy, interrupted sleep, sleep apnea, wakefulness, nocturnal
myoclonus, REM sleep interruptions, jet-lag, shift workers' sleep
disturbances, dyssomnias, night terror, insomnias associated with
depression, emotional/mood disorders, Alzheimer's disease or
cognitive impairment, as well as sleep walking and enuresis, and
sleep disorders which accompany aging; Alzheimer's sundowning;
conditions associated with circadian rhythmicity as well as mental
and physical disorders associated with travel across time zones and
with rotating shift-work schedules, conditions due to drugs which
cause reductions in REM sleep as a side effect; fibromyalgia;
syndromes which are manifested by non-restorative sleep and muscle
pain or sleep apnea which is associated with respiratory
disturbances during sleep; conditions which result from a
diminished quality of sleep; increasing learning; augmenting
memory; increasing retention of memory; eating disorders associated
with excessive food intake and complications associated therewith,
compulsive eating disorders, obesity (due to any cause, whether
genetic or environmental), obesity-related disorders overeating,
anorexia, bulimia, cachexia, dysregulated appetite control,
hypertension, diabetes, elevated plasma insulin concentrations and
insulin resistance, dyslipidemias, hyperlipidemia, endometrial,
breast, prostate and colon cancer, osteoarthritis, obstructive
sleep apnea, cholelithiasis, gallstones, heart disease, lung
disease, abnormal heart rhythms and arrythmias, myocardial
infarction, congestive heart failure, coronary heart disease, acute
and congestive heart failure; hypotension; hypertension; urinary
retention; osteoporosis; angina pectoris; myocardinal infarction;
ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers;
allergies; benign prostatic hypertrophy; chronic renal failure;
renal disease; impaired glucose tolerance; sudden death, polycystic
ovary disease, craniopharyngioma, the Prader-Willi Syndrome,
Frohlich's syndrome, GH-deficient subjects, normal variant short
stature, Turner's syndrome, and other pathological conditions
showing reduced metabolic activity or a decrease in resting energy
expenditure as a percentage of total fat-free mass, e.g, children
with acute lymphoblastic leukemia, metabolic syndrome, also known
as syndrome X, insulin resistance syndrome, reproductive hormone
abnormalities, sexual and reproductive dysfunction, such as
impaired fertility, infertility, hypogonadism in males and
hirsutism in females, fetal defects associated with maternal
obesity, gastrointestinal motility disorders, intestinal motility
dyskinesias, obesity-related gastro-esophageal reflux, hypothalmic
diseases, hypophysis diseases, respiratory disorders, such as
obesity-hypoventilation syndrome (Pickwickian syndrome),
breathlessness, cardiovascular disorders, inflammation, such as
systemic inflammation of the vasculature, arteriosclerosis,
hypercholesterolemia, hyperuricaemia, lower back pain, gallbladder
disease, gout, kidney cancer, increased anesthetic risk, reducing
the risk of secondary outcomes of obesity, such as reducing the
risk of left ventricular hypertrophy; diseases or disorders where
abnormal oscillatory activity occurs in the brain, including
depression, migraine, neuropathic pain, Parkinson's disease,
psychosis and schizophrenia, as well as diseases or disorders where
there is abnormal coupling of activity, particularly through the
thalamus; enhancing cognitive function, including cognitive
dysfunctions that comprise deficits in all types of attention,
learning and memory functions occurring transiently or chronically
in the normal, healthy, young, adult or aging population, and also
occurring transiently or chronically in psychiatric, neurologic,
cardiovascular and immune disorders; enhancing memory; increasing
memory retention; increasing immune response; increasing immune
function; hot flashes; night sweats; extending life span;
schizophrenia; muscle-related disorders that are controlled by the
excitation/relaxation rhythms imposed by the neural system such as
cardiac rhythm and other disorders of the cardiovascular system;
conditions related to proliferation of cells such as vasodilation
or vasorestriction and blood pressure; cancer; cardiac arrhythmia;
hypertension; congestive heart failure; conditions of the
genital/urinary system; disorders of sexual function and fertility;
adequacy of renal function; responsivity to anesthetics; mood
disorders, such as depression or more particularly depressive
disorders, for example, single episodic or recurrent major
depressive disorders and dysthymic disorders, or bipolar disorders,
for example, bipolar I disorder, bipolar II disorder and
cyclothymic disorder, mood disorders due to a general medical
condition, and substance-induced mood disorders; affective
neurosis; depressive neurosis; anxiety neurosis; anxiety disorders
including acute stress disorder, agoraphobia, generalized anxiety
disorder, obsessive-compulsive disorder, panic attack, panic
disorder, post-traumatic stress disorder, separation anxiety
disorder, social phobia, specific phobia, substance-induced anxiety
disorder and anxiety due to a general medical condition; acute
neurological and psychiatric disorders such as cerebral deficits
subsequent to cardiac bypass surgery and grafting, stroke, ischemic
stroke, cerebral ischemia, spinal cord trauma, head trauma,
perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage;
Huntington's Chorea; Huntington's disease and Tourette syndrome;
Cushing's syndrome/disease; basophile adenoma; prolactinoma;
hyperprolactinemia; hypophysis tumor/adenoma; hypothalamic
diseases; inflammatory bowel disease; gastric diskinesia; gastric
ulcers; Froehlich's syndrome; adrenohypophysis disease; hypophysis
disease; adrenohypophysis hypofunction; adrenohypophysis
hyperfunction; hypothalamic hypogonadism; Kallman's syndrome
(anosmia, hyposmia); functional or psychogenic amenorrhea;
hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal
dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders
of growth hormone deficiency; idiopathic growth deficiency;
dwarfism; gigantism; acromegaly; amyotrophic lateral sclerosis;
multiple sclerosis; ocular damage; retinopathy; cognitive
disorders; idiopathic and drug-induced Parkinson's disease;
muscular spasms and disorders associated with muscular spasticity
including tremors, epilepsy, convulsions, seizure disorders,
absence seisures, complex partial and generalized seizures;
Lennox-Gastaut syndrome; cognitive disorders including dementia
(associated with Alzheimer's disease, ischemia, trauma, vascular
problems or stroke, HIV disease, Parkinson's disease, Huntington's
disease, Pick's disease, Creutzfeldt-Jacob disease, perinatal
hypoxia, other general medical conditions or substance abuse);
delirium, amnestic disorders or age related cognitive decline;
schizophrenia or psychosis including schizophrenia (paranoid,
disorganized, catatonic or undifferentiated), schizophreniform
disorder, schizoaffective disorder, delusional disorder, brief
psychotic disorder, shared psychotic disorder, psychotic disorder
due to a general medical condition and substance-induced psychotic
disorder; dissociative disorders including multiple personality
syndromes and psychogenic amnesias; substance-related disorders,
substance use, substance abuse, substance seeking, substance
reinstatement, all types of psychological and physical addictions
and addictive behaviors, reward-related behaviors (including
substance-induced delirium, persisting dementia, persisting
amnestic disorder, psychotic disorder or anxiety disorder;
tolerance, addictive feeding, addictive feeding behaviors,
binge/purge feeding behaviors, dependence, withdrawal or relapse
from substances including alcohol, amphetamines, cannabis, cocaine,
hallucinogens, inhalants, morphine, nicotine, opioids,
phencyclidine, sedatives, hypnotics or anxiolytics); appetite,
taste, eating or drinking disorders; movement disorders, including
akinesias and akinetic-rigid syndromes (including Parkinson's
disease, drug-induced parkinsonism, postencephalitic parkinsonism,
progressive supranuclear palsy, multiple system atrophy,
corticobasal degeneration, parkinsonism-ALS dementia complex and
basal ganglia calcification), chronic fatigue syndrome, fatigue,
including Parkinson's fatigue, multiple sclerosis fatigue, fatigue
caused by a sleep disorder or a circadian rhythm disorder,
medication-induced parkinsonism (such as neuroleptic-induced
parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced
acute dystonia, neuroleptic-induced acute akathisia,
neuroleptic-induced tardive dyskinesia and medication-induced
postural tremor), Gilles de la Tourette's syndrome, epilepsy, and
dyskinesias [including tremor (such as rest tremor, essential
tremor, postural tremor and intention tremor), chorea (such as
Sydenham's chorea, Huntington's disease, benign hereditary chorea,
neuroacanthocytosis, symptomatic chorea, drug-induced chorea and
hemiballism), myoclonus (including generalised myoclonus and focal
myoclonus), tics (including simple tics, complex tics and
symptomatic tics), restless leg syndrome and dystonia (including
generalised dystonia such as iodiopathic dystonia, drug-induced
dystonia, symptomatic dystonia and paroxymal dystonia, and focal
dystonia such as blepharospasm, oromandibular dystonia, spasmodic
dysphonia, spasmodic torticollis, axial dystonia, dystonic writer's
cramp and hemiplegic dystonia); neurodegenerative disorders
including nosological entities such as
disinhibition-dementia-parkinsonism-amyotrophy complex;
pallido-ponto-nigral degeneration; epilepsy; seizure disorders;
attention deficit/hyperactivity disorder (ADHD); conduct disorder;
migraine (including migraine headache); headache; hyperalgesia;
pain; enhanced or exaggerated sensitivity to pain such as
hyperalgesia, causalgia, and allodynia; acute pain; burn pain;
atypical facial pain; neuropathic pain; back pain; complex regional
pain syndrome I and II; arthritic pain; sports injury pain; pain
related to infection e.g. HIV, post-chemotherapy pain; post-stroke
pain; post-operative pain; neuralgia; emesis, nausea, vomiting;
gastric dyskinesia; gastric ulcers; Kallman's syndrome (anosmia);
asthma; cancer; conditions associated with visceral pain such as
irritable bowel syndrome, and angina; eating disorders; urinary
incontinence; substance tolerance, substance withdrawal (including,
substances such as opiates, nicotine, tobacco products, alcohol,
benzodiazepines, cocaine, sedatives, hypnotics, etc.); psychosis;
schizophrenia; anxiety (including generalized anxiety disorder,
panic disorder, and obsessive compulsive disorder); mood disorders
(including depression, mania, bipolar disorders); trigeminal
neuralgia; hearing loss; tinnitus; neuronal damage including ocular
damage; retinopathy; macular degeneration of the eye; emesis; brain
edema; pain, including acute and chronic pain states, severe pain,
intractable pain, inflammatory pain, neuropathic pain,
post-traumatic pain, bone and joint pain (osteoarthritis),
repetitive motion pain, dental pain, cancer pain, myofascial pain
(muscular injury, fibromyalgia), perioperative pain (general
surgery, gynecological), chronic pain, neuropathic pain,
post-traumatic pain, trigeminal neuralgia, migraine and migraine
headache and other diseases related to general orexin system
dysfunction.
Thus, in certain embodiments the present invention may provide
methods for: enhancing the quality of sleep; augmenting sleep
maintenance; increasing REM sleep; increasing stage 2 sleep;
decreasing fragmentation of sleep patterns; treating insomnia and
all types of sleep disorders; treating or controlling sleep
disturbances associated with diseases such as neurological
disorders including neuropathic pain and restless leg syndrome;
treating or controlling addiction disorders; treating or
controlling psychoactive substance use and abuse; enhancing
cognition; increasing memory retention; treating or controlling
obesity; treating or controlling diabetes and appetite, taste,
eating, or drinking disorders; treating or controlling hypothalamic
diseases; treating or controlling depression; treating,
controlling, ameliorating or reducing the risk of epilepsy,
including absence epilepsy; treating or controlling pain, including
neuropathic pain; treating or controlling Parkinson's disease;
treating or controlling psychosis; treating or controlling
dysthymic, mood, psychotic and anxiety disorders; treating or
controlling depression, including major depression and major
depression disorder; treating or controlling bipolar disorder; or
treating, controlling, ameliorating or reducing the risk of
schizophrenia, in a mammalian patient in need thereof which
comprises administering to the patient a therapeutically effective
amount of a compound of the present invention.
The subject compounds could further be of potential use in a method
for the prevention, treatment, control, amelioration, or reduction
of risk of the diseases, disorders and conditions noted herein. The
dosage of active ingredient in the compositions of this invention
may be varied, however, it is necessary that the amount of the
active ingredient be such that a suitable dosage form is obtained.
The active ingredient may be administered to patients (animals and
human) in need of such treatment in dosages that will provide
optimal pharmaceutical efficacy. The selected dosage depends upon
the desired therapeutic effect, on the route of administration, and
on the duration of the treatment. The dose will vary from patient
to patient depending upon the nature and severity of disease, the
patient's weight, special diets then being followed by a patient,
concurrent medication, and other factors which those skilled in the
art will recognize. Generally, dosage levels of between 0.0001 to
10 mg/kg. of body weight daily are administered to the patient,
e.g., humans and elderly humans, to obtain effective antagonism of
orexin receptors. The dosage range will generally be about 0.5 mg
to 1.0 g. per patient per day which may be administered in single
or multiple doses. In one embodiment, the dosage range will be
about 0.5 mg to 500 mg per patient per day; in another embodiment
about 0.5 mg to 200 mg per patient per day; and in yet another
embodiment about 5 mg to 50 mg per patient per day. Pharmaceutical
compositions of the present invention may be provided in a solid
dosage formulation such as comprising about 0.5 mg to 500 mg active
ingredient, or comprising about 1 mg to 250 mg active ingredient.
The pharmaceutical composition may be provided in a solid dosage
formulation comprising about 1 mg, 5 mg, 10 mg, 25 mg, 30 mg, 50
mg, 80 mg, 100 mg, 200 mg or 250 mg active ingredient. For oral
administration, the compositions may be provided in the form of
tablets containing 1.0 to 1000 milligrams of the active ingredient,
such as 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400,
500, 600, 750, 800, 900, and 1000 milligrams of the active
ingredient for the symptomatic adjustment of the dosage to the
patient to be treated. The compounds may be administered on a
regimen of 1 to 4 times per day, such as once or twice per day. The
compounds may be administered before bedtime. For example, the
compounds may be administered about 1 Hour prior to bedtime, about
30 minutes prior to bedtime or immediately before bedtime.
The compounds of the present invention may be used in combination
with one or more other drugs in the treatment, prevention, control,
amelioration, or reduction of risk of diseases or conditions for
which compounds of the present invention or the other drugs may
have utility, where the combination of the drugs together are safer
or more effective than either drug alone. Such other drug(s) may be
administered, by a route and in an amount commonly used therefor,
contemporaneously or sequentially with a compound of the present
invention. When a compound of the present invention is used
contemporaneously with one or more other drugs, a pharmaceutical
composition in unit dosage form containing such other drugs and the
compound of the present invention is contemplated. However, the
combination therapy may also include therapies in which the
compound of the present invention and one or more other drugs are
administered on different overlapping schedules. It is also
contemplated that when used in combination with one or more other
active ingredients, the compounds of the present invention and the
other active ingredients may be used in lower doses than when each
is used singly. Accordingly, the pharmaceutical compositions of the
present invention include those that contain one or more other
active ingredients, in addition to a compound of the present
invention. The above combinations include combinations of a
compound of the present invention not only with one other active
compound, but also with two or more other active compounds.
Likewise, compounds of the present invention may be used in
combination with other drugs that are used in the prevention,
treatment, control, amelioration, or reduction of risk of the
diseases or conditions for which compounds of the present invention
are useful. Such other drugs may be administered, by a route and in
an amount commonly used therefor, contemporaneously or sequentially
with a compound of the present invention. When a compound of the
present invention is used contemporaneously with one or more other
drugs, a pharmaceutical composition containing such other drugs in
addition to the compound of the present invention is contemplated.
Accordingly, the pharmaceutical compositions of the present
invention include those that also contain one or more other active
ingredients, in addition to a compound of the present
invention.
The weight ratio of the compound of the present invention to the
second active ingredient may be varied and will depend upon the
effective dose of each ingredient. Generally, an effective dose of
each will be used. Thus, for example, when a compound of the
present invention is combined with another agent, the weight ratio
of the compound of the present invention to the other agent will
generally range from about 1000:1 to about 1:1000, such as about
200:1 to about 1:200. Combinations of a compound of the present
invention and other active ingredients will generally also be
within the aforementioned range, but in each case, an effective
dose of each active ingredient should be used. In such combinations
the compound of the present invention and other active agents may
be administered separately or in conjunction. In addition, the
administration of one element may be prior to, concurrent to, or
subsequent to the administration of other agent(s).
The compounds of the present invention may be administered in
combination with other compounds which are known in the art to be
useful for enhancing sleep quality and preventing and treating
sleep disorders and sleep disturbances, including e.g., sedatives,
hypnotics, anxiolytics, antipsychotics, antianxiety agents,
antihistamines, benzodiazepines, barbiturates, cyclopyrrolones,
GABA agonists, 5HT-2 antagonists including 5HT-2A antagonists and
5HT-2A/2C antagonists, histamine antagonists including histamine H3
antagonists, histamine H3 inverse agonists, imidazopyridines, minor
tranquilizers, melatonin agonists and antagonists, melatonergic
agents, other orexin antagonists, orexin agonists, prokineticin
agonists and antagonists, pyrazolopyrimidines, T-type calcium
channel antagonists, triazolopyridines, and the like, such as:
adinazolam, allobarbital, alonimid, alprazolam, amitriptyline,
amobarbital, amoxapine, armodafinil, APD-125, bentazepam,
benzoctamine, brotizolam, bupropion, busprione, butabarbital,
butalbital, capromorelin, capuride, carbocloral, chloral betaine,
chloral hydrate, chlordiazepoxide, clomipramine, clonazepam,
cloperidone, clorazepate, clorethate, clozapine, conazepam,
cyprazepam, desipramine, dexclamol, diazepam, dichloralphenazone,
divalproex, diphenhydramine, doxepin, EMD-281014, eplivanserin,
estazolam, eszopiclone, ethchlorynol, etomidate, fenobam,
flunitrazepam, flurazepam, fluvoxamine, fluoxetine, fosazepam,
gaboxadol, glutethimide, halazepam, hydroxyzine, ibutamoren,
imipramine, indiplon, lithium, lorazepam, lormetazepam, LY-156735,
maprotiline, MDL-100907, mecloqualone, melatonin, mephobarbital,
meprobamate, methaqualone, methyprylon, midaflur, midazolam,
modafinil, nefazodone, NGD-2-73, nisobamate, nitrazepam,
nortriptyline, ornortriptyline, oxazepam, paraldehyde, paroxetine,
pentobarbital, perlapine, perphenazine, phenelzine, phenobarbital,
prazepam, promethazine, propofol, protriptyline, quazepam,
ramelteon, reclazepam, roletamide, secobarbital, sertraline,
suproclone, TAK-375, temazepam, thioridazine, tiagabine,
tracazolate, tranylcypromaine, trazodone, triazolam, trepipam,
tricetamide, triclofos, trifluoperazine, trimetozine, trimipramine,
uldazepam, venlafaxine, zaleplon, zolazepam, zopiclone, zolpidem,
and salts thereof, and combinations thereof, and the like, or the
compound of the present invention may be administered in
conjunction with the use of physical methods such as with light
therapy or electrical stimulation.
In another embodiment, the subject compound may be employed in
combination with other compounds which are known in the art, either
administered separately or in the same pharmaceutical compositions,
including, but are not limited to: insulin sensitizers including
(i) PPAR.gamma. antagonists such as glitazones (e.g. ciglitazone;
darglitazone; englitazone; isaglitazone (MCC-555); pioglitazone;
rosiglitazone; troglitazone; tularik; BRL49653; CLX-0921; 5-BTZD),
GW-0207, LG-100641, and LY-300512, and the like); (iii) biguanides
such as metformin and phenformin; (b) insulin or insulin mimetics,
such as biota, LP-100, novarapid, insulin detemir, insulin lispro,
insulin glargine, insulin zinc suspension (lente and ultralente);
Lys-Pro insulin, GLP-1 (73-7) (insulintropin); and GLP-1
(7-36)-NH.sub.2); (c) sulfonylureas, such as acetohexamide;
chlorpropamide; diabinese; glibenclamide; glipizide; glyburide;
glimepiride; gliclazide; glipentide; gliquidone; glisolamide;
tolazamide; and tolbutamide; (d) .alpha.-glucosidase inhibitors,
such as acarbose, adiposine; camiglibose; emiglitate; miglitol;
voglibose; pradimicin-Q; salbostatin; CKD-711; MDL-25,637;
MDL-73,945; and MOR 14, and the like; (e) cholesterol lowering
agents such as (i) HMG-CoA reductase inhibitors (atorvastatin,
itavastatin, fluvastatin, lovastatin, pravastatin, rivastatin,
rosuvastatin, simvastatin, and other statins), (ii) bile acid
absorbers/sequestrants, such as cholestyramine, colestipol,
dialkylaminoalkyl derivatives of a cross-linked dextran;
Colestid.RTM.; LoCholest.RTM., and the like, (ii) nicotinyl
alcohol, nicotinic acid or a salt thereof, (iii)
proliferator-activater receptor a agonists such as fenofibric acid
derivatives (gemfibrozil, clofibrate, fenofibrate and
benzaflbrate), (iv) inhibitors of cholesterol absorption such as
stanol esters, beta-sitosterol, sterol glycosides such as
tiqueside; and azetidinones such as ezetimibe, and the like, and
(acyl CoA:cholesterol acyltransferase (ACAT)) inhibitors such as
avasimibe, and melinamide, (v) antioxidants, such as probucol, (vi)
vitamin E, and (vii) thyromimetics; (f) PPAR.alpha. agonists such
as beclofibrate, benzafibrate, ciprofibrate, clofibrate,
etofibrate, fenofibrate, and gemfibrozil; and other fibric acid
derivatives, such as Atromid.RTM., Lopid.RTM. and Tricor.RTM., and
the like, and PPAR.alpha. agonists as described in WO 97/36579; (g)
PPAR.delta. agonists, such as those disclosed in WO97/28149; (h)
PPAR .alpha./.delta. agonists, such as muraglitazar, and the
compounds disclosed in U.S. Pat. No. 6,414,002; (i) anti-obesity
agents, such as (1) growth hormone secretagogues, growth hormone
secretagogue receptor agonists/antagonists, such as NN703,
hexarelin, MK-0677, SM-130686, CP-424,391, L-692,429, and
L-163,255, and such as those disclosed in U.S. Pat. Nos. 5,536,716,
and 6,358,951, U.S. Patent Application Nos. 2002/049196 and
2002/022637, and PCT Application Nos. WO 01/56592 and WO 02/32888;
(2) protein tyrosine phosphatase-1B (PTP-1B) inhibitors; (3)
cannabinoid receptor ligands, such as cannabinoid CB.sub.1 receptor
antagonists or inverse agonists, such as rimonabant, taranabant,
AMT-251, and SR-14778 and SR 141716A (Sanofi Synthelabo), SLV-319
(Solvay), BAY 65-2520 (Bayer) and those disclosed in U.S. Pat. Nos.
5,532,237, 4,973,587, 5,013,837, 5,081,122, 5,112,820, 5,292,736,
5,624,941, 6,028,084, PCT Application Nos. WO 96/33159, WO
98/33765, WO98/43636, WO98/43635, WO 01/09120, WO98/31227,
WO98/41519, WO98/37061, WO00/10967, WO00/10968, WO97/29079,
WO99/02499, WO 01/58869, WO 01/64632, WO 01/64633, WO 01/64634,
WO02/076949, WO 03/007887, WO 04/048317, and WO 05/000809; (4)
anti-obesity serotonergic agents, such as fenfluramine,
dexfenfluramine, phentermine, and sibutramine; (5)
.beta.3-adrenoreceptor agonists, such as AD9677/TAK677
(Dainippon/Takeda), CL-316,243, SB 418790, BRL-37344, L-796568,
BMS-196085, BRL-35135A, CGP12177A, BTA-243, Trecadrine, Zeneca
D7114, SR 59119A; (6) pancreatic lipase inhibitors, such as
orlistat (Xenical.RTM.), Triton WR1339, RHC80267, lipstatin,
tetrahydrolipstatin, teasaponin, diethylumbelliferyl phosphate, and
those disclosed in PCT Application No. WO 01/77094; (7)
neuropeptide Y1 antagonists, such as BIBP3226, J-115814, BIBO 3304,
LY-357897, CP-671906, GI-264879A, and those disclosed in U.S. Pat.
No. 6,001,836, and PCT Patent Publication Nos. WO 96/14307, WO
01/23387, WO 99/51600, WO 01/85690, WO 01/85098, WO 01/85173, and
WO 01/89528; (8) neuropeptide Y5 antagonists, such as GW-569180A,
GW-594884A, GW-587081X, GW-548118X, FR226928, FR 240662, FR252384,
1229U91, GI-264879A, CGP71683A, LY-377897, PD-160170, SR-120562A,
SR-120819A and JCF-104, and those disclosed in U.S. Pat. Nos.
6,057,335; 6,043,246; 6,140,354; 6,166,038; 6,180,653; 6,191,160;
6,313,298; 6,335,345; 6,337,332; 6,326,375; 6,329,395; 6,340,683;
6,388,077; 6,462,053; 6,649,624; and 6,723,847, European Patent
Nos. EP-01010691, and EP-01044970; and PCT International Patent
Publication Nos. WO 97/19682, WO 97/20820, WO 97/20821, WO
97/20822, WO 97/20823, WO 98/24768; WO 98/25907; WO 98/25908; WO
98/27063, WO 98/47505; WO 98/40356; WO 99/15516; WO 99/27965; WO
00/64880, WO 00/68197, WO 00/69849, WO 01/09120, WO 01/14376; WO
01/85714, WO 01/85730, WO 01/07409, WO 01/02379, WO 01/02379, WO
01/23388, WO 01/23389, WO 01/44201, WO 01/62737, WO 01/62738, WO
01/09120, WO 02/22592, WO 0248152, and WO 02/49648; WO 02/094825;
WO 03/014083; WO 03/10191; WO 03/092889; WO 04/002986; and WO
04/031175; (9) melanin-concentrating hormone (MCH) receptor
antagonists, such as those disclosed in WO 01/21577 and WO
01/21169; (10) melanin-concentrating hormone 1 receptor (MCH1R)
antagonists, such as T-226296 (Takeda), and those disclosed in PCT
Patent Application Nos. WO 01/82925, WO 01/87834, WO 02/051809, WO
02/06245, WO 02/076929, WO 02/076947, WO 02/04433, WO 02/51809, WO
02/083134, WO 02/094799, WO 03/004027; (11) melanin-concentrating
hormone 2 receptor (MCH2R) agonist/antagonists; (12) orexin
receptor antagonists, such as SB-334867-A, and those disclosed in
patent publications herein; (13) serotonin reuptake inhibitors such
as fluoxetine, paroxetine, and sertraline; (14) melanocortin
agonists, such as Melanotan II; (15) Mc4r (melanocortin 4 receptor)
agonists, such as CHIR86036 (Chiron), ME-10142, and ME-10145
(Melacure), CHIR86036 (Chiron); PT-141, and PT-14 (Palatin); (16)
5HT-2 agonists; (17) 5HT2C (serotonin receptor 2C) agonists, such
as BVT933, DPCA37215, WAY161503, R-1065, and those disclosed in
U.S. Pat. No. 3,914,250, and PCT Application Nos. WO 02/36596, WO
02/48124, WO 02/10169, WO 01/66548, WO 02/44152, WO 02/51844, WO
02/40456, and WO 02/40457; (18) galanin antagonists; (19) CCK
agonists; (20) CCK-A (cholecystokinin-A) agonists, such as AR-R
15849, GI 181771, JMV-180, A-71378, A-71623 and SR14613, and those
described in U.S. Pat. No. 5,739,106; (21) GLP-1 agonists; (22)
corticotropin-releasing hormone agonists; (23) histamine receptor-3
(H3) modulators; (24) histamine receptor-3 (H3) antagonists/inverse
agonists, such as hioperamide, 3-(1H-imidazol-4-yl)propyl
N-(4-pentenyl)carbamate, clobenpropit, iodophenpropit, imoproxifan,
GT2394 (Gliatech), and O-[3-(1H-imidazol-4-yl)propanol]-carbamates;
(25) .beta.-hydroxy steroid dehydrogenase-1 inhibitors
(.beta.-HSD-1); (26) PDE (phosphodiesterase) inhibitors, such as
theophylline, pentoxifylline, zaprinast, sildenafil, amrinone,
milrinone, cilostamide, rolipram, and cilomilast; (27)
phosphodiesterase-3B (PDE3B) inhibitors; (28) NE (norepinephrine)
transport inhibitors, such as GW 320659, despiramine, talsupram,
and nomifensine; (29) ghrelin receptor antagonists, such as those
disclosed in PCT Application Nos. WO 01/87335, and WO 02/08250;
(30) leptin, including recombinant human leptin (PEG-OB, Hoffman La
Roche) and recombinant methionyl human leptin (Amgen); (31) leptin
derivatives; (32) BRS3 (bombesin receptor subtype 3) agonists such
as [D-Phe6,beta-Ala11,Phe13,Nle14]Bn(6-14) and
[D-Phe6,Phe13]Bn(6-13)propylamide, and those compounds disclosed in
Pept. Sci. 2002 August; 8(8): 461-75); (33) CNTF (Ciliary
neurotrophic factors), such as GI-181771 (Glaxo-SmithKline),
SR146131 (Sanofi Synthelabo), butabindide, PD170,292, and PD 149164
(Pfizer); (34) CNTF derivatives, such as axokine (Regeneron); (35)
monoamine reuptake inhibitors, such as sibutramine; (36) UCP-1
(uncoupling protein-1), 2, or 3 activators, such as phytanic acid,
4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propeny-
l]benzoic acid (TTNPB), retinoic acid; (37) thyroid hormone .beta.
agonists, such as KB-2611 (KaroBioBMS); (38) FAS (fatty acid
synthase) inhibitors, such as Cerulenin and C75; (39) DGAT1
(diacylglycerol acyltransferase 1) inhibitors; (40) DGAT2
(diacylglycerol acyltransferase 2) inhibitors; (41) ACC2
(acetyl-CoA carboxylase-2) inhibitors; (42) glucocorticoid
antagonists; (43) acyl-estrogens, such as oleoyl-estrone, disclosed
in del Mar-Grasa, M. et al., Obesity Research, 9:202-9 (2001); (44)
dipeptidyl peptidase IV (DP-IV) inhibitors, such as isoleucine
thiazolidide, valine pyrrolidide, NVP-DPP728, LAF237, P93/01, TSL
225, TMC-2A/2B/2C, FE 999011, P9310/K364, VIP 0177, SDZ 274-444,
sitagliptin; and the compounds disclosed in U.S. Pat. No.
6,699,871, WO 03/004498; WO 03/004496; EP 1 258 476; WO 02/083128;
WO 02/062764; WO 03/000250; WO 03/002530; WO 03/002531; WO
03/002553; WO 03/002593; WO 03/000180; and WO 03/000181; (46)
dicarboxylate transporter inhibitors; (47) glucose transporter
inhibitors; (48) phosphate transporter inhibitors; (49) Metformin
(Glucophage.RTM.); (50) Topiramate (Topimax>); (50) peptide YY,
PYY 3-36, peptide YY analogs, derivatives, and fragments such as
BIM-43073D, BIM-43004C (Olitvak, D. A. et al., Dig. Dis. Sci.
44(3):643-48 (1999)); (51) Neuropeptide Y2 (NPY2) receptor agonists
such NPY3-36, N acetyl [Leu(28,31)] NPY 24-36, TASP-V, and
cyclo-(28/32)-Ac-[Lys28-Glu32]-(25-36)-pNPY; (52) Neuropeptide Y4
(NPY4) agonists such as pancreatic peptide (PP), and other Y4
agonists such as 1229U91; (54) cyclooxygenase-2 inhibitors such as
etoricoxib, celecoxib, valdecoxib, parecoxib, lumiracoxib,
BMS347070, tiracoxib or JTE522, ABT963, CS502 and GW406381; (55)
Neuropeptide Y1 (NPY1) antagonists such as BIBP3226, J-115814, BIBO
3304, LY-357897, CP-671906, GI-264879A; (56) Opioid antagonists
such as nalmefene (Revex.RTM.), 3-methoxynaltrexone, naloxone,
naltrexone; (57) 11.beta. HSD-1 (11-beta hydroxy steroid
dehydrogenase type 1) inhibitors such as BVT 3498, BVT 2733, and
those disclosed in WO 01/90091, WO 01/90090, WO 01/90092, U.S. Pat.
No. 6,730,690 and US 2004-0133011; (58) aminorex; (59)
amphechloral; (60) amphetamine; (61) benzphetamine; (62)
chlorphentermine; (63) clobenzorex; (64) cloforex; (65) clominorex;
(66) clortermine; (67) cyclexedrine; (68) dextroamphetamine; (69)
diphemethoxidine, (70) N-ethylamphetamine; (71) fenbutrazate; (72)
fenisorex; (73) fenproporex; (74) fludorex; (75) fluminorex; (76)
furfurylmethylamphetamine; (77) levamfetamine; (78)
levophacetoperane; (79) mefenorex; (80) metamfepramone; (81)
methamphetamine; (82) norpseudoephedrine; (83) pentorex; (84)
phendimetrazine; (85) phenmetrazine; (86) picilorex; (87)
phytopharm 57; and (88) zonisamide, (89) neuromedin U and analogs
or derivatives thereof, (90) oxyntomodulin and analogs or
derivatives thereof, and (91) Neurokinin-1 receptor antagonists
(NK-1 antagonists) such as the compounds disclosed in: U.S. Pat.
Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595,
5,459,270, 5,494,926, 5,496,833, and 5,637,699.
In another embodiment, the subject compound may be employed in
combination with an anti-depressant or anti-anxiety agent,
including norepinephrine reuptake inhibitors (including tertiary
amine tricyclics and secondary amine tricyclics), selective
serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors
(MAOIs), reversible inhibitors of monoamine oxidase (RIMAs),
serotonin and noradrenaline reuptake inhibitors (SNRIs),
corticotropin releasing factor (CRF) antagonists,
.alpha.-adrenoreceptor antagonists, neurokinin-1 receptor
antagonists, atypical anti-depressants, benzodiazepines,
5-HT.sub.1A agonists or antagonists, especially 5-HT.sub.1A partial
agonists, and corticotropin releasing factor (CRF) antagonists.
Specific agents include: amitriptyline, clomipramine, doxepin,
imipramine and trimipramine; amoxapine, desipramine, maprotiline,
nortriptyline and protriptyline; citalopram, duloxetine,
fluoxetine, fluvoxamine, paroxetine and sertraline; isocarboxazid,
phenelzine, tranylcypromine and selegiline; moclobemide:
venlafaxine; aprepitant; bupropion, lithium, nefazodone, trazodone
and viloxazine; alprazolam, chlordiazepoxide, clonazepam,
chlorazepate, diazepam, halazepam, lorazepam, oxazepam and
prazepam; buspirone, flesinoxan, gepirone and ipsapirone, and
pharmaceutically acceptable salts thereof.
In another embodiment, the subject compound may be employed in
combination with anti-Alzheimer's agents; beta-secretase
inhibitors, such as verubecastat; gamma-secretase inhibitors;
growth hormone secretagogues; recombinant growth hormone; HMG-CoA
reductase inhibitors; NSAID's including ibuprofen; vitamin E;
anti-amyloid antibodies; CB-1 receptor antagonists or CB-1 receptor
inverse agonists; antibiotics such as doxycycline and rifampin;
N-methyl-D-aspartate (NMDA) receptor antagonists, such as
memantine; cholinesterase inhibitors such as galantamine,
rivastigmine, donepezil, and tacrine; growth hormone secretagogues
such as ibutamoren, ibutamoren mesylate, and capromorelin;
histamine H.sub.3 antagonists; AMPA agonists; PDE IV inhibitors;
GABA.sub.A inverse agonists; or neuronal nicotinic agonists.
In another embodiment, the subject compound may be employed in
combination with sedatives, hypnotics, anxiolytics, antipsychotics,
antianxiety agents, cyclopyrrolones, imidazopyridines,
pyrazolopyrimidines, minor tranquilizers, melatonin agonists and
antagonists, melatonergic agents, benzodiazepines, barbiturates,
5HT-2 antagonists, and the like, such as: adinazolam, allobarbital,
alonimid, alprazolam, amitriptyline, amobarbital, amoxapine,
bentazepam, benzoctamine, brotizolam, bupropion, busprione,
butabarbital, butalbital, capuride, carbocloral, chloral betaine,
chloral hydrate, chlordiazepoxide, clomipramine, clonazepam,
cloperidone, clorazepate, clorethate, clozapine, cyprazepam,
desipramine, dexclamol, diazepam, dichloralphenazone, divalproex,
diphenhydramine, doxepin, estazolam, ethchlorvynol, etomidate,
fenobam, flunitrazepam, flurazepam, fluvoxamine, fluoxetine,
fosazepam, glutethimide, halazepam, hydroxyzine, imipramine,
lithium, lorazepam, lormetazepam, maprotiline, mecloqualone,
melatonin, mephobarbital, meprobamate, methaqualone, midaflur,
midazolam, nefazodone, nisobamate, nitrazepam, nortriptyline,
oxazepam, paraldehyde, paroxetine, pentobarbital, perlapine,
perphenazine, phenelzine, phenobarbital, prazepam, promethazine,
propofol, protriptyline, quazepam, reclazepam, roletamide,
secobarbital, sertraline, suproclone, temazepam, thioridazine,
tracazolate, tranylcypromaine, trazodone, triazolam, trepipam,
tricetamide, triclofos, trifluoperazine, trimetozine, trimipramine,
uldazepam, venlafaxine, zaleplon, zolazepam, zolpidem, and salts
thereof, and combinations thereof, and the like, or the subject
compound may be administered in conjunction with the use of
physical methods such as with light therapy or electrical
stimulation.
In another embodiment, the subject compound may be employed in
combination with levodopa (with or without a selective
extracerebral decarboxylase inhibitor such as carbidopa or
benserazide), anticholinergics such as biperiden (optionally as its
hydrochloride or lactate salt) and trihexyphenidyl (benzhexol)
hydrochloride, COMT inhibitors such as entacapone, MOA-B
inhibitors, antioxidants, A2a adenosine receptor antagonists,
cholinergic agonists, NMDA receptor antagonists, serotonin receptor
antagonists and dopamine receptor agonists such as alentemol,
bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and
pramipexole.
In another embodiment, the subject compound may be employed in
combination with acetophenazine, alentemol, benzhexol,
bromocriptine, biperiden, chlorpromazine, chlorprothixene,
clozapine, diazepam, fenoldopam, fluphenazine, haloperidol,
levodopa, levodopa with benserazide, levodopa with carbidopa,
lisuride, loxapine, mesoridazine, molindolone, naxagolide,
olanzapine, pergolide, perphenazine, pimozide, pramipexole,
risperidone, sulpiride, tetrabenazine, trihexyphenidyl,
thioridazine, thiothixene or trifluoperazine.
In another embodiment, the subject compound may be employed in
combination with a compound from the phenothiazine, thioxanthene,
heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine
and indolone classes of neuroleptic agent. Suitable examples of
phenothiazines include chlorpromazine, mesoridazine, thioridazine,
acetophenazine, fluphenazine, perphenazine and trifluoperazine.
Suitable examples of thioxanthenes include chlorprothixene and
thiothixene. An example of a dibenzazepine is clozapine. An example
of a butyrophenone is haloperidol. An example of a
diphenylbutylpiperidine is pimozide. An example of an indolone is
molindolone. Other neuroleptic agents include loxapine, sulpiride
and risperidone.
In another embodiment, the subject compound may be employed in
combination with a nicotine agonist or a nicotine receptor partial
agonist such as varenicline, opioid antagonists (e.g., naltrexone
(including naltrexone depot), antabuse, and nalmefene),
dopaminergic agents (e.g., apomorphine), ADD/ADHD agents (e.g.,
methylphenidate hydrochloride (e.g., Ritalin.RTM. and
Concerta.RTM.), atomoxetine (e.g., Strattera.RTM.), a monoamine
oxidase inhibitor (MAOI), amphetamines (e.g., Adderall.RTM.)) and
anti-obesity agents, such as apo-B/MTP inhibitors, 11Beta-hydroxy
steroid dehydrogenase-1 (11Beta-HSD type 1) inhibitors, peptide
YY3-36 or analogs thereof, MCR-4 agonists, CCK-A agonists,
monoamine reuptake inhibitors, sympathomimetic agents, .beta.3
adrenergic receptor agonists, dopamine receptor agonists,
melanocyte-stimulating hormone receptor analogs, 5-HT2c receptor
agonists, melanin concentrating hormone receptor antagonists,
leptin, leptin analogs, leptin receptor agonists, galanin receptor
antagonists, lipase inhibitors, bombesin receptor agonists,
neuropeptide-Y receptor antagonists (e.g., NPY Y5 receptor
antagonists), thyromimetic agents, dehydroepiandrosterone or
analogs thereof, glucocorticoid receptor antagonists, other orexin
receptor antagonists, such as suvorexant, glucagon-like peptide-1
receptor agonists, ciliary neurotrophic factors, human
agouti-related protein antagonists, ghrelin receptor antagonists,
histamine 3 receptor antagonists or inverse agonists, and
neuromedin U receptor agonists, and pharmaceutically acceptble
salts thereof.
In another embodiment, the subject compound may be employed in
combination with an anoretic agent such as aminorex, amphechloral,
amphetamine, benzphetamine, chlorphentermine, clobenzorex,
cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine,
dextroamphetamine, diethylpropion, diphemethoxidine,
N-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex,
fenproporex, fludorex, fluminorex, furfurylmethylamphetamine,
levamfetamine, levophacetoperane, mazindol, mefenorex,
metamfepramone, methamphetamine, norpseudoephedrine, pentorex,
phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine,
picilorex and sibutramine; selective serotonin reuptake inhibitor
(SSRI); halogenated amphetamine derivatives, including
chlorphentermine, cloforex, clortermine, dexfenfluramine,
fenfluramine, picilorex and sibutramine; and pharmaceutically
acceptble salts thereof.
In another embodiment, the subject compound may be employed in
combination with an opiate agonist, a lipoxygenase inhibitor, such
as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such
as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as
an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of
nitric oxide or an inhibitor of the synthesis of nitric oxide, a
non-steroidal antiinflammatory agent, or a cytokine-suppressing
antiinflammatory agent, for example with a compound such as
acetaminophen, asprin, codiene, fentanyl, ibuprofen, indomethacin,
ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal
analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly,
the subject compound may be administered with a pain reliever; a
potentiator such as caffeine, an H2-antagonist, simethicone,
aluminum or magnesium hydroxide; a decongestant such as
phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline,
ephinephrine, naphazoline, xylometazoline, propylhexedrine, or
levo-desoxy-ephedrine; an antiitussive such as codeine,
hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a
diuretic; and a sedating or non-sedating antihistamine.
The compounds of the present invention may be administered by oral,
parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV,
intracisternal injection or infusion, subcutaneous injection, or
implant), by inhalation spray, nasal, vaginal, rectal, sublingual,
or topical routes of administration and may be formulated, alone or
together, in suitable dosage unit formulations containing
conventional non-toxic pharmaceutically acceptable carriers,
adjuvants and vehicles appropriate for each route of
administration. In addition to the treatment of warm-blooded
animals such as mice, rats, horses, cattle, sheep, dogs, cats,
monkeys, etc., the compounds of the invention may be effective for
use in humans.
The pharmaceutical compositions for the administration of the
compounds of this invention may conveniently be presented in dosage
unit form and may be prepared by any of the methods well known in
the art of pharmacy. All methods include the step of bringing the
active ingredient into association with the carrier which
constitutes one or more accessory ingredients. In general, the
pharmaceutical compositions are prepared by uniformly and
intimately bringing the active ingredient into association with a
liquid carrier or a finely divided solid carrier or both, and then,
if necessary, shaping the product into the desired formulation. In
the pharmaceutical composition the active object compound is
included in an amount sufficient to produce the desired effect upon
the process or condition of diseases. As used herein, the term
"composition" is intended to encompass a product comprising the
specified ingredients in the specified amounts, as well as any
product which results, directly or indirectly, from combination of
the specified ingredients in the specified amounts.
Pharmaceutical compositions intended for oral use may be prepared
according to any method known to the art for the manufacture of
pharmaceutical compositions and such compositions may contain one
or more agents selected from the group consisting of sweetening
agents, flavoring agents, coloring agents and preserving agents in
order to provide pharmaceutically elegant and palatable
preparations. Tablets contain the active ingredient in admixture
with non-toxic pharmaceutically acceptable excipients which are
suitable for the manufacture of tablets. These excipients may be
for example, inert diluents, such as calcium carbonate, sodium
carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, corn starch, or
alginic acid; binding agents, for example starch, gelatin or
acacia, and lubricating agents, for example magnesium stearate,
stearic acid or talc. The tablets may be uncoated or they may be
coated by known techniques to delay disintegration and absorption
in the gastrointestinal tract and thereby provide a sustained
action over a longer period. Compositions for oral use may also be
presented as hard gelatin capsules wherein the active ingredient is
mixed with an inert solid diluent, for example, calcium carbonate,
calcium phosphate or kaolin, or as soft gelatin capsules wherein
the active ingredient is mixed with water or an oil medium, for
example peanut oil, liquid paraffin, or olive oil. Aqueous
suspensions contain the active materials in admixture with
excipients suitable for the manufacture of aqueous suspensions.
Oily suspensions may be formulated by suspending the active
ingredient in a suitable oil. Oil-in-water emulsions may also be
employed. Dispersible powders and granules suitable for preparation
of an aqueous suspension by the addition of water provide the
active ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Pharmaceutical
compositions of the present compounds may be in the form of a
sterile injectable aqueous or oleagenous suspension. The compounds
of the present invention may also be administered in the form of
suppositories for rectal administration. For topical use, creams,
ointments, jellies, solutions or suspensions, etc., containing the
compounds of the present invention may be employed. The compounds
of the present invention may also be formulated for administered by
inhalation. The compounds of the present invention may also be
administered by a transdermal patch by methods known in the
art.
Several methods for preparing the compounds of this invention are
illustrated in the following Schemes and Examples. Starting
materials are made according to procedures known in the art (e.g.
PCT Patent Publications WO2001/68609, WO2004/085403, WO2005/118548,
WO2008/147518, WO2009/143033 and WO2010/048012) or as illustrated
herein. The following abbreviations are used herein: Me: methyl;
Et: ethyl; t-Bu: tert-butyl; Ar: aryl; Ph: phenyl; BINAP:
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl; Bn: benzyl; Ac:
acetyl; Boc: tert-butyloxy carbonyl; BSA: bovine serum albumin;
CbzCl: benzylchloroformate; CDI: carbonyl diimidazole; DCM:
dichloromethane; DCE: dichloroethane; DEAD:
diethylazodicarboxylate; DIPEA: N,N-diisopropylethylamine; DMF:
N,N-dimethylformamide; DMSO: dimethylsulfoxide; CH.sub.2Cl.sub.2:
dichloromethane; EDC:
N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide; Et.sub.3N:
triethylamine; EtOAc: ethyl acetate; EtOH: ethanol; HCl: hydrogen
chloride; HOAt: 1-hydroxy-7-azabenzotriazole; HOBT:
hydroxybenzotriazole hydrate; HPLC: high performance liquid
chromatography; Hunig's base: N,N-diisopropylethylamine; MeOH:
methanol; MgSO.sub.4: magnesium sulfate; MTBE: methyl tert-butyl
ether; NaHCO.sub.3: sodium bicarbonate; NaOH: sodium hydroxide;
NMM: N-methylmorpholine; PtO.sub.2: platinum oxide; PyClu:
1-(chloro-1-pyrrolidinylmethylene)-pyrrolidinium
hexafluorophosphate; rt: room temperature; SOCl.sub.2: thionyl
chloride; T3P:
2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide;
THF: tetrahydrofuran; TFA: trifluoracetic acid; X-Phos:
2-(dicyclohexyl-phosphino)-2',4',6'-triisopropylbiphenyl. The
compounds of the present invention can be prepared in a variety of
fashions.
In some cases the final product may be further modified, for
example, by manipulation of substituents. These manipulations may
include, but are not limited to, reduction, oxidation, alkylation,
acylation, and hydrolysis reactions which are commonly known to
those skilled in the art. In some cases the order of carrying out
the foregoing reaction schemes may be varied to facilitate the
reaction or to avoid unwanted reaction products. The following
examples are provided so that the invention might be more fully
understood. These examples are illustrative only and should not be
construed as limiting the invention in any way.
Example 1
##STR00008## ##STR00009##
Methyl
4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]c-
arbonyl}-piperidin-3-yl]sulfanyl}pyridine-3-carboxylate
Step 1: .+-.Benzyl trans-5-hydroxy-2-methylpiperidine-1-carboxylate
(1)
To a solution of 6-methylpyridin-3-ol (20.0 g, 0.183 mol) in MeOH
(200 mL) was added concentrated HCl (15.43 mL, 0.1850 mol) and
PtO.sub.2 (2.40 g, 0.011 mol). The resulting mixture was heated to
70.degree. C. at 50 PSI overnight. The reaction was filtered over
solka-floc to remove the PtO.sub.2 and concentrated to a solid to
provide .+-.trans-6-methylpiperidin-3-ol hydrochloride. The crude
solid was taken on without further purification. A mixture of
.+-.trans-6-methylpiperidin-3-ol hydrochloride (14.0 g, 0.092 mol)
in CH.sub.2Cl.sub.2 (150 mL) was cooled at 0.degree. C.
Triethylamine (51.5 mL, 0.369 mol) was added slowly. CbzCl (13.59
mL, 0.092 mol) was added dropwise, keeping the temperature below
20.degree. C. The reaction was allowed to warm overnight to room
temperature. The reaction was quenched by addition of water and
diluted further with additional CH.sub.2Cl.sub.2. The layers were
separated and the organics were dried over MgSO.sub.4 and
concentrated. The crude material was purified by silica gel
gradient chromatography (0-75% ethyl acetate in hexanes), providing
the titled compound as an oil.
Step 2: Benzyl (2R,5S)-5-hydroxy-2-methylpiperidine-1-carboxylate
(2)
To a solution of oxalyl chloride (13.17 mL, 0.150 mol) in
CH.sub.2Cl.sub.2 (250 mL) at -78.degree. C. was added DMSO (14.23
mL, 0.201 mol) dropwise. The reaction was aged for 20 min at
-78.degree. C., then .+-.trans-6-methylpiperidin-3-ol hydrochloride
(25.0 g, 0.100 mol) was added dropwise over 10 min and aged for an
additional 10 min before the triethylamine (41.9 mL, 0.301 mol) was
added dropwise over 5 min at -78.degree. C. The reaction was warmed
to room temperature, then quenched with addition of half-saturated,
aqueous NaHCO.sub.3 and additional CH.sub.2Cl.sub.2. The layers
were separated and the organics were dried with MgSO.sub.4 and
concentrated. The crude material was purified by silica gel
gradient chromatography (0-50% ethyl acetate in hexanes), providing
.+-.benzyl 2-methyl-5-oxopiperidine-1-carboxylate as a yellow oil.
To a solution of THF (200 mL) and MeOH (11 mL) was added lithium
borohydride (2 M, 89 mL, 0.18 mol). Some gas evolution and small
exotherm were observed. The reaction was aged at room temperature
for 30 min before being cooled to -10.degree. C. with an
acetone:ice bath. .+-.Benzyl 2-methyl-5-oxopiperidine-1-carboxylate
(22.0 g, 0.089 mol) was then added dropwise, keeping the
temperature below -5.degree. C. The reaction was then aged at
-10.degree. C. for 30 min. The reaction was quenched by adding
half-saturated, aqueous NaHCO.sub.3, then extracted with EtOAc. The
layers were separated and the organics dried with MgSO.sub.4. The
organics were concentrated to give
.+-.benzyl-5-hydroxy-2-methylpiperidine-1-carboxylate as a crude,
colorless oil. Chiral separation (SFC, IC 30.times.250 mm, 15%
MeOH/CO.sub.2, 70 ml/min, 115 mg/ml in MeOH) of the crude
.+-.benzyl-5-hydroxy-2-methylpiperidine-1-carboxylate provided the
titled compound as enantiopure material.
Step 3: (3S,6R)-6-Methylpiperidin-3-ol (3)
A solution of benzyl
(2R,5S)-5-hydroxy-2-methylpiperidine-1-carboxylate (5.00 g, 20.1
mmol), and palladium (10 wt % on activated carbon, 2.13 g) in
degassed EtOH (130 mL) was stirred for 3 nights under an atmosphere
of hydrogen gas. The degassed mixture was then filtered over
celite, washing with EtOH. The filtrate was concentrated to give
the titled compound as a crude, yellow oil which was used without
further purification.
Step 4:
(2-(2H-1,2,3-Triazol-2-yl)phenyl)((2R,5S)-5-hydroxy-2-methylpiperi-
din-1-yl)methanone (4)
A solution of (3S,6R)-6-methylpiperidin-3-ol (2.36 g, 20.5 mmol),
2-(2H-1,2,3-triazol-2-yl)benzoic acid (4.65 g, 24.6 mmol), EDC
(7.86 g, 41.0 mmol), 1-hydroxy-7-azabenzotriazole (5.58 g, 41.0
mmol), and triethylamine (8.57 mL, 61.5 mmol) in DMF (130 mL) was
stirred at 50.degree. C. overnight, then diluted with saturated
aqueous sodium bicarbonate and extracted 5.times. with ethyl
acetate. The organics were washed with brine, dried over magnesium
sulfate, filtered, and concentrated. The crude material was
purified by silica gel gradient chromatography (0-100% ethyl
acetate in hexanes), providing the titled compound as a
peach-colored solid. LRMS m/z (M+H) 287.4 found, 287.1
required.
Step 5:
(3S,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6-methylpiperidin-3-y-
l methanesulfonate (5)
A solution of
2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5S)-5-hydroxy-2-methylpiperidin-1-yl-
)methanone (0.300 g, 1.05 mmol), 4-dimethylaminopyridine (0.013 g,
0.10 mmol), and Hunig's base (0.27 mL, 0.0016 mmol) in
dichloromethane (10.5 mL) was cooled to 0.degree. C. and treated
with methanesulfonyl chloride (0.10 mL, 0.0013 mmol). After 3
hours, the mixture was poured into saturated aqueous sodium
bicarbonate and extracted 2.times. with dichloromethane. The
combined organic fractions were washed with brine, dried over
sodium sulfate, filtered, and concentrated in vacuo, providing the
title compound as a sticky off-white foam which was used without
further purification. LRMS m/z (M+H) 365.3 found, 365.2
required.
Step 6:
S-43R,6R)-1-(2-(2H-1,2,3-Triazol-2-yl)benzoyl)-6-methylpiperidin-3-
-yl)ethanethiolate (6)
A solution of
(3S,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl
methanesulfonate (0.400 g, 1.10 mmol) in DMF (5.5 mL) was purged
with nitrogen, treated with potassium thioacetate (0.251 g, 2.20
mmol), and heated to 80.degree. C. overnight. The reaction was
poured into water and extracted 2.times. with ethyl acetate. The
organic fraction was washed with brine, dried over magnesium
sulfate, filtered, and concentrated. The residue was purified by
silica gel gradient chromatography (0-65% ethyl acetate in
hexanes), providing the title compound. LRMS m/z (M+H) 345.3 found,
345.2 required.
Step 7:
(2-(2H-1,2,3-Triazol-2-yl)phenyl)((2R,5R)-5-mercapto-2-methylpiper-
idin-1-yl)methanone
A solution of
S-((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)et-
hanethiolate (0.293 g, 0.851 mmol) in methanol (6 mL) was purged
with nitrogen and treated with sodium thiomethoxide (0.067 g, 0.96
mmol) and stirred at RT. After 1.5 hours, the reaction was quenched
with saturated aqueous ammonium chloride, diluted with water, and
extracted 2.times. with ethyl acetate. The combined organic
fractions were washed with brine, dried over magnesium sulfate,
filtered, and concentrated. The residue was purified by silica gel
gradient chromatography (0-70% ethyl acetate in hexanes), providing
the title compound. LRMS m/z (M+H) 303.4 found, 303.2 required.
Step 8: Methyl 2-chloro-4-methylnicotinate (8)
A solution of 2-chloro-4-methylnicotinic acid (0.300 g, 1.75 mmol)
in DMF (3.5 mL) was treated with iodomethane (0.14 mL, 2.3 mmol)
and potassium carbonate (0.362 g, 2.62 mmol) and allowed to stir at
RT for 30 min. The mixture was diluted with ethyl acetate and
washed with saturated sodium bicarbonate and brine, dried over
sodium sulfate, filtered, and concentrated, providing the title
compound as an orange oil that was used without further
purification.
Step 9: Methyl
4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbony-
l}piperidin-3-yl]sulfanyl}pyridine-3-carboxylate
A solution of
(2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-mercapto-2-methylpiperidin-1--
yl)methanone (0.020 g, 0.066 mmol) and methyl
2-chloro-4-methylnicontinate (0.016 g, 0.086 mmol) in DMSO (0.6 mL)
was purged with nitrogen, treated with cesium carbonate (0.032 g,
0.10 mmol) and heated to 65.degree. C. overnight. The reaction was
filtered and purified by reverse phase preparatory HPLC, providing
the title compound. HRMS m/z (M+H) 452.1745 found, 452.1751
required.
Table 1
The following compounds were prepared according to the general
procedure provided in Example 1, substituting the appropriate
2-halopyridine for methyl 2-chloro-4-methylnicotinate. The starting
materials are either commercially available or may be prepared from
commercially available reagents using conventional reactions well
known in the art.
##STR00010##
TABLE-US-00001 LRMS or HRMS Example R Name (M + H.sup.+) 2
##STR00011## 2-methyl-6-{[(3R,6R)-6-methyl-
1-{[2-(2H-1,2,3-triazol-2- yl)phenyl]carbonyl}piperidin-3-
yl]sulfanyl}pyridine-4-carbonitrile Calc'd 419.1651, found 419.1641
3 ##STR00012## methyl 2-{[(3R,6R)-6-methyl-1-
{[2-(2H-1,2,3-triazol-2- yl)phenyl]carbonyl}piperidin-3-
yl]sulfanyl}pyridine-3-carboxylate Calc'd 438.1596, found 438.1591
4 ##STR00013## methyl 4-iodo-2-{[(3R,6R)-6-methyl-
1-{[2-(2H-1,2,3-triazol-2- yl)phenyl]carbonyl}piperidin-3-
yl]sulfanyl}pyridine-3-carboxylate Calc'd 564.0522, found
564.0857
Example 7
##STR00014##
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperidi-
n-3-yl]sulfanyl}pyridine
A solution of
(2-(2H-1,2,3-Triazol-2-yl)phenyl)((2R,5S)-5-hydroxy-2-methylpiperidin-1-y-
l)methanone (Example 1, 4, 0.063 g, 0.17 mmol)) in DMF (1.7 mL) was
treated with pyridine-1-thiol (0.46 mmol) and cesium carbonate
(0.130 g, 0.399 mmol) and heated to 80.degree. C. for 72 h. The
mixture was diluted with water and extracted 2.times. with ethyl
acetate. The combined organic fractions were washed with brine,
dried over magnesium sulfate, filtered, and concentrated. The
residue was purified by silica gel gradient chromatography (0-50%
ethyl acetate in hexanes), providing the title compound. HRMS m/z
(M+H) 380.1541 found, 380.1542 required.
Table 2
The following compounds were prepared according to the general
procedure provided in Example 7, substituting the appropriate aryl
thiol for pyridine-1-thiol. The starting materials are either
commercially available or may be prepared from commercially
available reagents using conventional reactions well known in the
art.
##STR00015##
TABLE-US-00002 LRMS or HRMS Example R Name (M + H.sup.+) 8
##STR00016## 2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}-5-
(trifluoromethyl)pyridine Calc'd 448.1417, found 448.1413 9
##STR00017## 2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile
Calc'd 405.1495, found 405.1495 10 ##STR00018##
4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-3-carbonitrile
Calc'd 419.1651, found 419.1649 11 ##STR00019##
4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine Calc'd
394.1698, found 394.1692 12 ##STR00020##
2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-3-carbonitrile
Calc'd 405.1495, found 405.1492 13 ##STR00021## methyl
2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carboxylate
Calc'd 438.1596, found 438.1594
Example 14
##STR00022##
2-{[(3R,6R)-1-{[6-Methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl]carbonyl}--
6-methylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile
Step 1: Methyl
2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)t-
hio)nicotinate (9)
The title compound was prepared by the procedure described for the
synthesis of
(3S,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl
methanesulfonate (Example 1, 5), substituting (2R,5S)-benzyl
5-hydroxy-2-methylpiperidine-1-carboxylate for
2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5
S)-5-hydroxy-2-methylpiperidin-1-yl)methanone. LRMS m/z (M+H) 328.3
found, 328.2 required.
Step 2: (2R,5R)-Benzyl
5-((4-cyanopyridin-2-yl)thio)-2-methylpiperidine-1-carboxylate
(10)
The title compound was prepared by the procedure described for the
synthesis of
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine (Example 7), substituting methyl
2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)t-
hio)nicotinate for
(2-(2H-1,2,3-Triazol-2-yl)phenyl)((2R,5S)-5-hydroxy-2-methylpiperidin-1-y-
l)methanone, and substituting 2-mercaptoisonicotinonitrile for
pyridine-1-thiol. LRMS m/z (M+H) 368.3 found, 368.2 required.
Step 3: 2-(((3R,6R)-6-Methylpiperidine-2-yl)thio)isonicotinonitrile
(11)
A solution of (2R,5R)-benzyl
5-((4-cyanopyridin-2-yl)thio)-2-methylpiperidine-1-carboxylate
(1.06 g, 2.88 mmol) in dichloromethane (58 mL) was treated with
dimethyl sulfide (21.3 mL, 0.288 mol) and boron trifluoride
etherate (3.65 mL, 13.8 mmol). The mixture was stirred at RT for
4.5 h, then poured into water and concentrated ammonium hydroxide.
The reaction was partitioned and the aqueous layer was extracted
with dichloromethane. The combined organic fractions were washed
with brine, dried over magnesium sulfate, filtered, and
concentrated. The crude residue was purified by silica gel gradient
chromatography (0-10% methanol in dichloromethane), providing the
titled compound as a yellow oil. LRMS m/z (M+H) 234.3 found, 234.1
required.
Step 4:
2-{[(3R,6R)-1-{[6-Methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl]ca-
rbonyl}-6-methylpiperidin-3-yl]sulfanyl}pyridine-4-carbonitrile
(Example 14)
The title compound was prepared by the procedure described for the
synthesis of
(2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5S)-5-hydroxy-2-methylpiperidin-1-y-
l)methanone (Example 1, 4), substituting
2-(((3R,6R)-6-methylpiperidine-2-yl)thio)isonicotinonitrile for
(3S,6R)-6-methylpiperidin-3-ol, and substituting
6-methoxy-2-(2H-1,2,3-triazol-2-yl)nicotinic acid for
2-(2H-1,2,3-triazol-2-yl)benzoic acid. HRMS m/z (M+H) 436.1538
found, 436.1553 required.
Table 3
The following compounds were prepared according to the general
procedure provided in Example 7, substituting the appropriate
carboxylic acid for 6-methoxy-2-(2H-1,2,3-triazol-2-yl)nicotinic
acid. The starting materials are either commercially available or
may be prepared from commercially available reagents using
conventional reactions well known in the art.
##STR00023##
TABLE-US-00003 LRMS or HRMS Example R Name (M + H.sup.+) 15
##STR00024## 2-{[(3R,6R)-6-methyl-1-{[4-(2H-1,2,3-
triazol-2-yl)pyridin-3- yl]carbonyl}piperidin-3-
yl]sulfanyl}pyridine-4-carbonitrile Calc'd 406.1447, found 406.1452
16 ##STR00025## 2-{[(3R,6R)-1-{[2-fluoro-6-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
423.1401, found 423.1402 17 ##STR00026##
2-{[(3R,6R)-1-{[2-methoxy-6-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
435.16, found 435.1603 18 ##STR00027##
2-{[(3R,6R)-6-methyl-1-{[3-methyl-2- (2H-1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile
Calc'd 419.1651, found 419.1653 19 ##STR00028##
2-{[(3R,6R)-1-{[3-fluoro-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
423.1401, found 423.1401 20 ##STR00029##
2-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
439.1105, found 439.1115 21 ##STR00030##
2-{[(3R,6R)-1-{[4-fluoro-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
423.1401, found 423.1405 22 ##STR00031##
2-{[(3R,6R)-6-methyl-1-{[4-methyl-2- (2H-1,2,3-triazol-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile
Calc'd 419.1651, found 419.1653 23 ##STR00032##
2-{[(3R,6R)-1-{[4-methoxy-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
435.16, found 435.1607 24 ##STR00033##
2-{[(3R,6R)-1-{[5-bromo-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
483.06, found 483.0596 25 ##STR00034##
2-{[(3R,6R)-1-{[5-chloro-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
439.1105, found 439.1107 26 ##STR00035##
3-({(2R,5R)-5-[(4-cyanopyridin-2- yl)sulfanyl]-2-methylpiperidin-1-
yl}carbonyl)-4-(2H-1,2,3-triazol-2- yl)benzamide Calc'd 448.1553,
found 448.1552 27 ##STR00036##
2-{[(3R,6R)-6-methyl-1-{[4-(2H-1,2,3- triazol-2-yl)isothiazol-3-
yl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile Calc'd
412.1012, found 412.1015 28 ##STR00037##
2-{[(3R,6R)-1-(biphenyl-2-ylcarbonyl)-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
414.1637, found 414.1638 29 ##STR00038##
2-({(3R,6R)-6-methyl-1-[(2- phenoxyphenyl)carbonyl]piperidin-3-
yl}sulfanyl)pyridine-4-carbonitrile Calc'd 430.1586, found 430.1590
30 ##STR00039## 2-({(3R,6R)-1-[(2- cyclopropylphenyl)carbonyl]-6-
methylpiperidin-3-yl}sulfanyl)pyridine-4- carbonitrile Calc'd
378.1637, found 378.1642 31 ##STR00040##
2-{[(3R,6R)-6-methyl-1-{[2-(1-methyl- 1H-pyrazol-4-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile
Calc'd 418.1698, found 418.1701 32 ##STR00041##
2-({(3R,6R)-6-methyl-1-[(2-
phenylpyridin-3-yl)carbonyl]piperidin-3-
yl}sulfanyl)pyridine-4-carbonitrile Calc'd 415.1589, found 415.1592
33 ##STR00042## 2-{[(3R,6R)-6-methyl-1-{[2-(1-
methylethoxy)phenyl]carbonyl} piperidin-
3-yl]sulfanyl}pyridine-4-carbonitrile Calc'd 396.1742, found
396.1746 34 ##STR00043## 2-{[(3R,6R)-6-methyl-1-{[2-
(methylsulfanyl)phenyl]carbonyl}
piperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd 384.1201,
found 384.1205 35 ##STR00044## 2-{[(3R,6R)-1-{[4-cyano-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine-4- carbonitrile Calc'd
430.1447, found 430.1450 36 ##STR00045##
2-{[(3R,6R)-1-{[4-ethoxy-2-(2H-1,2,3-
triazol-2-yl)phenyl]carbonyl}-6-
methylpiperidin-3-yl]sulfanyl}pyridine- 4-carbonitrile Calc'd
449.1756, found 449.1757 37 ##STR00046##
2-{[(3R,6R)-6-methyl-1-{[2-(tetrahydro- 2H-pyran-4-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile
Calc'd 422.1898, found 422.1902 38 ##STR00047##
2-{[(3R,6R)-6-methyl-1-{[2-(tetrahydro- 2H-pyran-2-
yl)phenyl]carbonyl}piperidin-3- yl]sulfanyl}pyridine-4-carbonitrile
Calc'd 422.1898, found 422.1900 39 ##STR00048##
2-({(3R,6R)-6-methyl-1-[(2-pyrrolidin-1-
ylphenyl)carbonyl]piperidin-3- yl}sulfanyl)pyridine-4-carbonitrile
Calc'd 407.1902, found 407.1906
Example 40
##STR00049##
2-({(3R,6R)-6-Methyl-1-[(2-pyrimidin-2-ylthiophen-3-yl)carbonyl]piperidin--
3-yl}sulfanyl)pyridine-4-carbonitrile
Step 1: Potassium 2-(pyrimidin-2-yl)thiophene-3-carboxylate
(12)
A solution of 2-bromo-3-thiophene carboxylic acid (3.35 g, 16.2
mmol) in methanol (50 mL) was cooled to 0.degree. C. and saturated
with gaseous HCl. The solution was heated to 60.degree. C.
overnight, then concentrated in vacuo. The residue was redissolved
in ethyl acetate, washed with saturated aqueous sodium bicarbonate
and brine, dried over sodium sulfate, filtered, and concentrated,
providing methyl 2-bromothiophene-3-carboxylate as yellow oil. LRMS
m/z (M+H) 221.1 found, 221.0 required. A solution of methyl
2-bromothiophene-3-carboxylate (1.74 g, 7.87 mmol),
2-(tributylstannyl)pyrimidine (4.36 g, 11.81 mmol), cesium fluoride
(4.78 g, 31.5 mmol), and copper(I) iodide (0.450 g, 2.36 mmol) in
DMF (16 mL) in a pressure vessel was purged subsurface with
nitrogen and treated with palladium tetrakis (0.455 g, 0.394 mmol).
The mixture was sealed and heated at 120.degree. C. overnight. The
reaction was partitioned between ethyl acetate and water and
filtered through celite. The organic layer was washed with
saturated aqueous sodium bicarbonate and brine, dried over
magnesium sulfate, filtered, and concentrated. The residue was
purified by silica gel gradient chromatography (0-30% ethyl acetate
in hexanes), providing methyl
2-(pyrimidin-2-yl)thiophene-3-carboxylate as a yellow solid. LRMS
m/z (M+H) 221.2 found, 221.1 required. A solution of methyl
2-(pyrimidin-2-yl)thiophene-3-carboxylate (0.695 g, 3.16 mmol) and
potassium trimethylsilanolate (0.506 g, 3.94 mmol) in THF (16 mL)
was stirred at RT overnight, then diluted with ether and filtered
through a glass frit. The solids were washed with ether, and the
filtrate was concentrated, providing the title compound as a beige
solid. LRMS m/z (M+H) 207.3 found, 207.1 required.
Step 2:
2-({(3R,6R)-6-Methyl-1-[(2-pyrimidin-2-ylthiophen-3-yl)carbonyl]pi-
peridin-3-yl}sulfanyl)pyridine-4-carbonitrile (Example 40)
A solution of
2-(((3R,6R)-6-methylpiperidine-2-yl)thio)isonicotinonitrile
(Example 14, 11, 0.020 g, 0.086 mmol), potassium
2-(pyrimidin-2-yl)thiophene-3-carboxylate (0.019 mg, 0.094 mmol),
and Hunig's base (0.019 mL, 0.11 mmol) in DMF (0.3 mL) was treated
with
2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide
(T3P, 50% in EtOAc, 0.102 mL, 0.171 mmol) and stirred at 50.degree.
C. overnight. The reaction was concentrated and purified by reverse
phase preparatory HPLC, providing the title compound. HRMS m/z
(M+H) 422.111 found, 422.1107 required.
Table 4
The following compounds were prepared according to the general
procedure provided in Example 40, substituting the appropriate
carboxylic acid for potassium
2-(pyrimidin-2-yl)thiophene-3-carboxylate. The starting materials
are either commercially available or may be prepared from
commercially available reagents using conventional reactions well
known in the art.
##STR00050##
TABLE-US-00004 LRMS or HRMS Example R Name (M + H.sup.+) 41
##STR00051## 2-({(3R,6R)-6-methyl-1-[(2- pyrimidin-2-
ylphenyl)carbonyl]piperidin-3- yl}sulfanyl)pyridine-4-carbonitrile
Calc'd 416.1542, found 416.1549 42 ##STR00052##
2-({(3R,6R)-6-methyl-1-[(3- pyrimidin-2-ylthiophen-2-
yl)carbonyl]piperidin-3- yl}sulfanyl)pyridine-4-carbonitrile Calc'd
422.1106, found 422.1108 43 ##STR00053##
2-({(3R,6R)-1-[(6-methoxy-2- pyrimidin-2-ylpyridin-3-yl)carbonyl]-
6-methylpiperidin-3- yl}sulfanyl)pyridine-4-carbonitrile Calc'd
447.1601, found 447.1599
Example 44
##STR00054##
2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-yl)thiophen-3-yl]carbonyl}p-
iperidin-3-yl]sulfanyl}pyridine-4-carbonitrile
Step 1: 2-(2H)-1,2,3-Triazol-2-yl)thiophene-3-carboxylic acid
(13)
A solution of 2-bromo-3-thiophene carboxylic acid (1.50 g, 7.24
mmol), 1H-1,2,3-triazole (0.600 g, 8.69 mmol), potassium carbonate
(2.00 g, 14.5 mmol), and copper iodide (0.138 g, 0.724 mmol) in DMF
(36.2 mL) was purged subsurface with nitrogen and heated to
75.degree. C. for 96 h. The reaction was diluted with water, washed
with ether, and acidified with conc. HCl. The acidic aqueous
solution was extracted 3.times. with ethyl acetate and the combined
organic fractions were washed with brine, dried over magnesium
sulfate, filtered, and concentrated. The crude material was
purified by silica gel gradient chromatography [0-70% (1% acetic
acid in ethyl acetate) in hexanes], providing the title compound as
an off-white solid. LRMS m/z (M+H) 196.2 found, 196.1 required.
Step 2:
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)thiophen-3-yl]ca-
rbonyl}piperidin-3-yl]sulfanyl}pyridine-4-carbonitrile (Example
44)
The title compound was prepared by the procedure described for the
synthesis of
(2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5S)-5-hydroxy-2-methylpiperidin-1-y-
l)methanone (Example 1, 4), substituting
2-(((3R,6R)-6-methylpiperidine-2-yl)thio)isonicotinonitrile
(Example 14, 11) for (3S,6R)-6-methylpiperidin-3-ol, and
substituting 2-(2H)-1,2,3-triazol-2-yl)thiophene-3-carboxylic acid
for 2-(2H-1,2,3-triazol-2-yl)benzoic acid. HRMS m/z (M+H) 411.1064
found, 411.1059 required.
Example 48
##STR00055##
2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperidi-
n-3-yl]sulfanyl}pyridine-3-carboxylic acid
A solution of methyl
2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperid-
in-3-yl]sulfanyl}pyridine-3-carboxylate (Example 3, 0.036 g, 0.082
mmol) in THF (1.4 mL) was treated with sodium hydroxide (1 M, 0.12
mL, 0.12 mmol) and stirred at RT for 4 nights. Additional sodium
hydroxide (1 M, 0.025 mL, 0.025 mmol) was added and the mixture was
stirred another night at RT. The reaction was concentrated, diluted
with water, and treated with conc. HCl to acidic pH. The mixture
was extracted 2.times. with ethyl acetate and the combined organic
fractions were washed with brine, dried over magnesium sulfate,
filtered, and concentrated. The residue was purified by silica gel
gradient chromatography (0-20% methanol in dichloromethane,
providing the title compound. HRMS m/z (M+H) 424.1424 found,
424.1438 required.
Example 49
##STR00056##
Methyl
4-methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]-
carbonyl}piperidin-3-yl]sulfanyl}pyridine-3-carboxylate
A solution of methyl
4-iodo-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}-
piperidin-3-yl]sulfanyl}pyridine-3-carboxylate (Example 4, 0.014 g,
0.025 mmol) in methanol (20% wt in methanol, 0.25 mL was treated
with tetrabutylammonium methoxide (0.068 g, 0.050 mmol) and heated
to 45.degree. C. overnight. The mixture was treated with additional
tetrabutylammonium methoxide (0.10 g, 0.075 mmol) and heated to
60.degree. C. for 2 nights. Additional tetrabutylammonium methoxide
(0.14 g, 0.10 mmol) and the mixture was heated to 60.degree. C. for
5 nights. The mixture was diluted with saturated aqueous sodium
bicarbonate and water and extracted 2.times. with ethyl acetate.
The combined organic fractions were washed with brine, dried over
magnesium sulfate, filtered, and concentrated. The residue was
purified by silica gel gradient chromatography (0-90% ethyl acetate
in hexanes), providing the title compound. HRMS m/z (M+H) 468.1708
found, 468.1700 required.
Table 11
The following table shows representative data for the compounds of
the Examples as orexin receptor antagonists as determined by the
assays described herein.
TABLE-US-00005 hOX2R FLIPR hOX1R FLIPR Example IC.sub.50 (nM)
IC.sub.50 (nM) 1 22.2 27.8 2 82.9 1538 3 23.9 48.1 4 23.6 54.4 7
179 1629 8 322 596 9 13.5 1411 10 24.2 634 11 20.0 440 12 No data
No data 13 297 6306 14 149 10000 15 No data No data 16 51.4 2350 17
51.2 5878 18 14.4 803 19 20.8 2548 20 15.5 1027 21 26.1 2720 22
49.0 1495 23 224 7821 24 14.9 489 25 214 4855 26 No data No data 27
No data No data 28 16.7 279 29 62.7 10000 30 18.3 4066 31 30.3 3190
32 71.9 10000 33 29.4 6841 34 75.4 8722 35 No data No data 36 No
data No data 37 No data No data 38 36.6 10000 39 103 10000 40 19.0
2240 41 18.9 1580 42 5.3 3557 43 864 10000 44 18.8 3918 45 21.5
45.3 46 5226 10000 47 552 6835 48 626.5 6544 49 11.1 73.2
As indicated by the data herein, the compounds of the present
examples provide functional selectivity for the orexin-2 receptor
over the orexin-1 receptor. The distinction in potency between the
orexin-2 receptor and the orexin-1 receptor in the whole cell FLIPR
functional assay provides enhanced predictive value for determining
in vivo efficacy. Increasing the functional selectivity for the
orexin-2 receptor reduces the potential for dual receptor
antagonism in vivo. Such greater functional selectivity may provide
benefits over other orexin receptor antagonists that are known in
the art.
While the invention has been described and illustrated with
reference to certain particular embodiments thereof, those skilled
in the art will appreciate that various adaptations, changes,
modifications, substitutions, deletions, or additions of procedures
and protocols may be made without departing from the spirit and
scope of the invention.
* * * * *